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ABSTRACT
Activation of NFκB pathway has been implicated in several malignancies and plays a
role in many key processes including tumor initiation and progression. The NFκB pathway
is activated when TNFα in the tumor microenvironment binds to its receptor, eventually
leading to the phosphorylation of the kinase IKKβ. Once active, IKKβ phosphorylates IκBα,
a protein that functions to sequester NFκB in the cytosol of resting cells. The
phosphorylation of IκBα leads to its degradation in the proteasome and allows NFκB to
translocate to the nucleus where it can drive gene transcription. The sulfhydryl groups on
solvent-exposed cysteine (Cys) residues of the key NFκB pathway proteins IKKβ and p65
serve as critical targets for NFκB pathway inhibition through covalent modification. The
Natarajan lab

previously reported an isatin-derived spirocyclic

α-methylene-γ-

butyrolactone analog 19, that covalently binds to IKKβ and p65 resulting in NFκB pathway
inhibition. Analog 19 also showed synergistic tumor growth inhibition with cisplatin in an
orthotopic ovarian cancer model without inducing any overt toxicity. To determine the
proteome wide targets of analog 19, we conducted pull-down MS with alkyne-tagged 19
treated lysates. This identified >100 proteins as potential targets of analog 19. Based on
these results we hypothesized that dimers of analog 19 will crosslink proteins in the IKK
complex and inhibit NFκB pathway. Synthesis and evaluation of the dimers showed that
dimers n3 and n7 were more potent than analog 19 in inhibiting nuclear translocation of
NFκB and the linker length contributed to their efficacy. The molecular basis for this was
attributed to the formation of irreversible covalent bonds between the surface exposed
cysteine residues of p65 and IKKβ and other proteins within the IKK complex resulting in
higher molecular weight protein complexes.
Analyses of the pull-down MS data also revealed that analog 19 binds to a number of
proteins involved in protein processing in the ER and protein folding. This suggested that
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the dimers could induce the unfolded protein response (UPR). Indeed, the dimers induced
UPR and activated the PERK/eIF2α/CHOP arm of the UPR leading to robust apoptotic
cell death in the cancer cells when compared to immortalized non-transformed cells. The
dimers were ~3-9 -fold more potent than the analog 19 in inhibiting cancer cell growth.
The potency was modulated by the linker length. We also showed that like analog 19 the
Michael acceptor in the dimers is critical for activity against cancer cells. In summary
studies presented in this dissertation demonstrate that dimers of the isatin-derived
spirocyclic NFκB inhibitor analog 19, potently inhibits cancer cell growth and induce
apoptosis by crosslinking NFκB pathway proteins and inducing UPR.
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CHAPTER 1: INTRODUCTION
NFκB pathway
NFκB family of proteins are inducible transcription factors that are involved in
regulating cellular growth, host-immunity and inflammatory response by inducing
transcription of many proinflammatory and growth-related genes. Additionally, they are
involved in either protecting cells from DNA damage or inducing cytokine mediated
apoptosis depending on the cell type and the type of inducer.[1, 2] The NFκB signaling
pathway is a cascade of multiple ubiquitination and phosphorylation steps. NFκB
transcription factor (Nuclear factor κB also known as RelA or NFκB3 or p65), in resting
cells, is bound to its endogenous inhibitor IκBα (Inhibitor of κB) in the cytoplasm. In
response to pro-inflammatory stimuli, IκBα is phosphorylated, ubiquitinated and tagged for
degradation. Degradation of IκBα leads to the release and nuclear translocation of p65.[3]
NFκB pathway is activated by a variety of stimuli, cytokines such as TNFα and IL-1,
LPS and ligands of various pattern-recognition receptors (PRRs), T-cell receptors (TCR),
B-cell receptor (BCR), genotoxic stress and oxidative stress.[4] Tumor necrosis factor-α
(TNFα), a pro-inflammatory cytokine activates the canonical NFκB pathway. Activation of
the canonical NFκB pathway is mediated by the trimerization of the TNF receptor, which
recruits an adapter protein TNF receptor-associated death domain (TRADD), an E3 ligase
TNFR-associated factor2 (TRAF2), and a kinase receptor interacting protein-1 (RIP1).[58] This leads to a series of ubiquitination and phosphorylation events, wherein TRAF2
mediates Lys63-linked polyubiquitination of RIP1, leading to TAB2 mediated recruitment
of TAK1/TAB1/TAB2 complex. This activates TAK1, an upstream kinase for the JNK
pathway, and triggers the subsequent phosphorylation-activation of IKK-complex.[9]
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The IKK-complex also referred to as IKK-signalosome is a ~900 kDa complex
comprised of two kinases (IKKβ and IKKα) and a regulatory protein IKKγ (NFκB essential
modulator, NEMO).[3, 10, 11] Hsp90 and cdc37 are also part of this complex as
chaperones.[12] The 900 kDa size suggests the presence of other transient and/or
permanent members of the complex, which are yet to be identified and validated. IKKα
and IKKβ have an N-terminal kinase domain, a helix-loop-helix (HLH) that regulates the
kinase activity and a leucine zipper (LZ) that facilitates homo- or hetero-dimerization.[13]
An IKKγ interaction domain located at the C-terminus facilitates interaction of IKKα and
IKKβ (a.a. 701-746) with IKKγ (a.a. 44-111 located at the N-terminal).[14, 15] Upon
activation of the pathway the ubiquitin binding domain present on NEMO undergoes K63
polyubiquitination which recruits TAK1 to the IKK complex. TAK1 phosphorylates IKKβ on
two serine residues (Ser 177 and 181) present in the activation loop of the kinase
domain.[13, 16] Structural and biochemical studies indicate an alternate mechanism of
activation i.e., trans-autophosphorylation of IKKβ.[17] Activated IKKβ phosphorylates IκBα
at two N-terminal serine residues 32 and 36 leading to its polyubiquitination through
Lys48-linked ubiquitin chains, catalyzed by SCFβTrCP type E3-ligase and subsequent
proteasomal degradation.[18] The IκB proteins contains the ankyrin domain that is
responsible for interacting with the nuclear localizing signal of p65, thereby inhibiting its
nuclear localization. Upon IκBα degradation, p65 is free to translocate to nucleus and
activate gene expression.[19]
In addition to p65, the NFκB family of transcription factors consist of four additional
proteins: RelB, c-Rel p50/105 (NFκB1) and p52/100 (NFκB2). All the proteins in the NFκB
family contain the Rel homology domain (RHD) that is involved in DNA binding,
dimerization, and nuclear transport.[20-22] RelB, c-Rel, and p65 also contain a
transactivation domain, whereas p50 and p52 don’t. The differential gene expression
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observed with NFκB pathway activation is due to the heterodimerization of different NFκB
proteins with different family members upon stimulation by various factors. Since p50 and
p52 don’t have the transactivation domain, their homo dimers act as transcriptional
repressors and act as transcriptional activators only when they heterodimerize with other
Rel proteins that contain a transactivation domain.[4]
Not only is NFκB pathway activated by numerous factors, it also regulates expression
of numerous genes (~400 genes).[21] The NFκB driven gene expression is involved in
immune and inflammatory responses, which include 27 different genes encoding for
cytokines (such as IL1β, TNFα), chemokines, antigen presenting proteins, and receptors
involved in immune recognition, neutrophil adhesion and migration.[23] NFκB driven gene
expression is involved in regulating apoptosis and cellular proliferation, which include
among others genes encoding the TNF receptor-associated factors TRAF1 and TRAF2,
the Bcl-2 homolog A1/Bfl-1 and Bcl-X L , Inhibitor of apoptosis IAPs, immediate early gene
on X-radiation-1 long (IEX-1L), and cyclin D1.[2, 24] An autoregulatory positive and
negative feedback loops are characteristic of NFκB. Proteins involved in positively or
negatively regulating the pathway are also under the control of NFκB. Dysfunction in these
loops lead to pathological conditions for example, chronic inflammation occurs when
negative regulation of the NFκB pathway is circumvented leading to constitutive NFκB
activation.[25]
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Figure 1. Pictorial representation of canonical NFκB signaling pathway.
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NFκB and its role in cancer
Since the NFκB signaling pathway regulates so many important cell survival and
growth promoting genes, dysfunction in any one of its multiple regulators could lead to
disastrous effects. Dysregulation of NFκB signaling pathway is implicated in various
severe disease conditions including arthritis, asthma, neurodegenerative diseases,
chronic inflammatory disease, and cancer.[26, 27] NFκB signaling pathway is
constitutively active in a variety of cancers, including leukemia, lymphoma, breast,
pancreatic, and ovarian cancer, and plays a significant role in tumor initiation, progression
and drug resistance.[24] Studies with surgically resected tissues samples showed
elevated levels of activated IKK in tumor samples when compared to normal tissue. NFκB
has a paradoxical role in cancer, one being tumor-immunosurveillance, wherein the NFκB
activity regulates the elimination of transformed cells and the other in initiation and
progression of cancer, wherein NFκB activity provides a cell survival mechanism for the
transformed cells. The tumor-immunosurveillance is not efficient in eliminating all
transformed cells and consequently a subset of transformed cells overcome immune
response mediated death. This is because elevated NFκB activity leads to upregulated
anti-apoptotic genes thus providing a subset of cancer cells an escape mechanism.[28]
NFκB signaling has been implicated in cancer progression, tumor angiogenesis, and
metastasis by regulating epithelial to mesenchymal transition and up-regulating matrix
metalloproteinases, VEGF and associated receptors.[29] This pathway has also been
implicated in drug-resistance in several cancers.[30-34]
NFκB pathway activation has been implicated as a tumor promoter in chronic
inflammation-related cancers.[35, 36] NFκB activity plays an important role in tumor
initiation and progression in Kras-induced pancreatic cancer and lung cancer.[37, 38]
Constitutive activation of NFκB pathway leads to enhanced metastasis and
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chemoresistance in breast, colon and lymphatic cancer.[39-41] Lymphoid malignancies
have been shown to have mutations in NFκB signaling genes. B-cell lymphomas such as
Hodgkin lymphomas were found to have amplification of RelA.[42] Hepatocellular
carcinoma is also associated with chronic inflammation and NFκB associated antiapoptotic gene expression contributes to their survival. Increased risk of colon cancer in
patients with inflammatory bowel disease (IBD) is seen due to elevated NFκB activity.[43]
NFκB has been shown to inhibit apoptosis and enhance proliferation in cancer stem cells
(CSCs).[44]
In ovarian cancer and glioblastoma, NFκB activation is associated with poor outcome
and more aggressive behavior. Deregulation of NFκB pathway in ovarian cancer results
in overexpression of NFκB target genes that regulate cell cycle progression, survival,
angiogenesis and invasion.[45, 46] In epithelial ovarian cancer, elevated levels of NFκB
is found in the nucleus and this correlates with advanced metastatic stage of the disease.
Patients with nuclear NFκB have lower cumulative survival rate (20%) and median survival
(24 months) than patients that tested negative (survival rate 46.2% and median survival
39 months).[45, 47] NFκB pathway contributes to chemoresistance in ovarian cancer cell
lines. It was found that NFκB pathway is partly responsible for CD44+ ovarian cancer stem
cells showing resistance to chemotherapeutic agents. Conversely, in multiple studies, it
was found that inhibiting NFκB activity or knocking out NFκB genes showed anti-tumor
effects. This highlights the value of finding inhibitors that target the different components
of NFκB pathway to improve survival in patients with abnormal NFκB activity.

NFκB Inhibitors:
Since NFκB pathway plays an important role in a several cellular processes, targeting
NFκB pathway proteins could lead to potential on-target toxicities. Therefore, the design
of NFκB targeted therapy requires a thorough understanding of the multiple levels of NFκB
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regulation in cancer and normal cells. Bortezomib, a ubiquitin-proteasome inhibitor inhibits
NFκB activity by blocking the degradation of IκBα. Bortezomib was approved by the FDA
for newly diagnosed and relapsed multiple myeloma.[48] Despite bortezomib’s efficacy in
hematologic cancers, it proved ineffective in solid tumors. Another inhibitor that is effective
in inhibiting NFκB activity is curcumin, a natural product derived from turmeric (Curcumin
longa) that has anti-inflammatory activity. Curcumin is shown to sensitize cancer cells to
chemotherapeutic agents but its activity is limited due to poor bioavailability.[49] These
treatment options do not selectively target NFκB. Other strategies to inhibit the NFκB
pathway include antibodies against TNFα, inhibiting the phosphorylation of IκBα or IKK
activation, and direct inhibitors of p65 either by inhibiting the nuclear translocation of p65
or inhibiting its DNA binding property. The vast majority of NFκB inhibitors inhibit p65
binding to the DNA or the phosphorylation of IKKβ or IκBα.[50]

NFκB and Covalent Inhibitors
Currently, there is a rising trend of covalently inhibiting the therapeutic targets for
cancer therapy. One such approach is appending an electrophilic group to a reversible
kinase inhibitor, which targets and forms a covalent bond with the sulfhydryl group of a
non-catalytic cysteine residue. Thiol reactive compounds such as nimbolide and
withaferin-A covalently modify cysteine 179 of IKKβ which ultimately leads to inhibition of
phosphorylation of IKKβ and its activity. Dehydroxymethylepoxyquinomicin (DHMEQ), an
analog of antibiotic epoxyquinomicin C is another covalent NFκB inhibitor.[51] DHMEQ
binds to Cys residues of p65 and Rel homology proteins, inhibits their nuclear localization
and DNA binding.[52] DHMEQ apart from ameliorating various inflammation related
conditions in mice show activity against malignant breast carcinoma and hormoneinsensitive prostate cancer.[51, 53-55] Other irreversible covalent inhibitors that target the
cysteine residues of IKK proteins like helenalin and parthenolide derived from naturally
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occurring sesquiterpene lactone. These are also being used as NFκB modulators in many
disease models. Helenalin binds to Cys38 of p65 and inhibits the DNA binding ability of
p65, thus inhibiting the canonical NFκB pathway.[56] Parthenolide is derived from a
medicinal herb Feverfew. It inhibits the IKKβ activity by covalently binding to Cys179
present in the kinase domain. It is also found to inhibit p65’s DNA binding ability by
covalently binding to Cys38 present in the DNA binding domain of p65.[57, 58] Only a few
clinical trials have been done for the NFκB inhibitors so far despite conducting various preclinical tests demonstrating great efficacy in cancer models. This is largely due to off-target
effects and toxicity.

Targeting the Cysteineome:
Cysteine (Cys) though less frequently present in protein sequences (< 2%) is an
important, nucleophilic, naturally occurring amino acid involved in many biochemical and
structural functions such as stabilizing the tertiary and quaternary structure, catalytic, and
regulatory.[59] Cysteine has a reactive sulfhydryl group that undergoes oxidation to form
disulfide bridges that are known to stabilize protein structure. Sulfhydryl/thiol group act as
reducing agents and form endogenous antioxidant defense system.[60] Cysteines
involved in the structural or catalytic functions are highly conserved within families and
targeting them could lead to selectivity issues. Presence of surface exposed cysteine
residues not involved in catalytic or structural functions, are less conserved, and could be
easily modulated with covalent drug-like molecules.[61, 62] Also, due to presence of low
abundance of cysteine in the protein sequences allow for selective and precise alterations.
Under oxidative stress, cysteines readily oxidize and form disulfides, sulfonic acids, or
other Cys-based products.[59] Some cysteine modifications are responsible for changing
electrostatic properties of the proteins molecular surface consequently regulate the protein
functions such as protein-protein interactions. For targeting cysteines an electrophilic
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group present on the inhibitor facilitates bond formation with the nucleophilic thiol
moiety.[63]

Michael acceptor on a spirocyclic isatin core:
The sulfhydryl groups on cysteine (Cys) residues of IKKβ and p65 have been
previously targeted using parthenolide, a sesquiterpene lactone natural product. The
Michael acceptor in the α-methylene-γ-butyrolactone of parthenolide is critical for activity
against IKKβ and p65.[57, 58] Due to structural and functional limitations of parthenolide,
analogs containing α-methylene-γ-butyrolactone moiety (business end of parthenolide,
responsible for its inhibitory activity) were synthesized in our lab and screened to identify
pathway specific inhibitor. This led to the identification of an isatin derived spirocyclic core
with an α-methylene-γ-butyrolactone moiety (analog 19) that inhibits the NFκB pathway
by covalently binding to IKKβ and p65. Analog 19 showed comparable activity to ML-120B
(a known IKKβ inhibitor). In a dose-response study, analog 19 showed low-µM inhibitory
activity in the TNFα-induced IKKβ-mediated NF-κB activity assay and was comparable to
Parthenolide.

Also,

irreversible

inhibition

of

IKKβ

resulted

in

reduced

IκBα

phosphorylation. Analog 19 also inhibited cancer cell growth and induced apoptosis.
Covalent inhibitors have been notorious for their idiosyncratic effects, but with analog 19,
no toxicity was observed in orthotopic ovarian cancer model with dose of less than 10
mg/kg. This is consistent with a retrospective clinical study in which the authors found that
covalent inhibitors dosed at 10mg or less did not exhibit the idiosyncratic toxicities.
Additionally, analog 19 showed synergistic effects with cisplatin in orthotopic ovarian
cancer model without showing any toxicity.[64]
Since analog 19 covalently binds to cysteines residues on p65 and IKKβ, we
hypothesized that a dimer of analog 19 with an appropriate linker will cross-link the NFκB
proteins, inactivate the pathway through a novel mechanism and enhance the potency of
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the inhibition. We also wanted to test if we were to duplicate the functional end of the
molecule (Michael acceptor) in a single compound, will the dimer (analog 19 with
duplicated functional moieties) cross link NFκB proteins to inhibit NFκB and potentially
forming aggregates of proteins to induce UPR. To this end, the chemist in the lab (Dr.
Sandeep Rana) synthesized a novel series of dimeric covalent inhibitors that conjugated
p65 to other proteins, inhibiting NFκB activity and induced UPR. Developing small
molecule inhibitors that stabilize p65 interaction with other proteins to inhibit its function is
novel and innovative.

ER stress and Unfolded Protein Response:
Checkpoints and signaling molecules constantly monitor cellular systems for cytotoxic
or genotoxic stress. Various cytoprotective measures are employed to resolve the stress
and to maintain cellular homeostasis. Adverse conditions such as hypoxia, pH changes,
nutrient deprivation, etc., among others induce endoplasmic reticulum (ER) stress. In
situations where the ER stress is not resolved, programmed cell death is initiated to protect
the host.[65]
An imbalance between protein folding capacity and folding demand, results in the
accumulation of misfolded proteins in the ER, leading to ER stress. Unfolded protein
response (UPR) is a mechanism for protecting cells from misfolded/unfolded protein
induced cell death. Glucose regulated protein 78 kD (GRP78), also referred to as BiP (an
ER chaperone) is a sensor of UPR.[66] UPR is regulated by multiple signaling pathways
that monitor the ER for the proper folding of proteins. The three central components of
UPR are the transmembrane ER signaling proteins inositol requiring enzyme 1 (IRE1),
double-stranded RNA-activated protein kinase- like ER kinase (PERK), and activating
transcription factor 6 (ATF6). BiP controls the activation of these proteins, by binding to
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them and regulating their function.[67-69] Upon sensing ER stress, BiP dissociates from
the three transmembrane proteins to activate UPR.
Dissociation of BiP from IRE1 results in its activation. Activated IRE1 is involved in Xbox binding protein-1 (XBP1) mRNA splicing in the cytoplasm.[70] The cytosolic domain
of IRE1 acts as an endoribonuclease removing a 26 base intron from the XBP1 mRNA.
This splicing leads to a change in the reading frame resulting in translation of the spliced
XBP1 that functions as a transcription factor to induce expression of ER stress response
genes

including

ER chaperone BiP

and ER-associated degradation

(ERAD)

components.[71-73] Overexpression of BiP improves protein folding capacity of the ER
and returns cells to its resting state by binding to and inactivating IRE1.
Accumulation of misfolded/unfolded proteins in the ER also results in the
homodimerization of PERK which leads to its activation via transphosphorylation.
Activated PERK phosphorylates translation initiation factor eIF2α leading to attenuation of
translation initiation by inhibition of 80S ribosome assembly. Since this attenuation occurs
immediately in response to UPR activation, this results in transient decrease in protein
synthesis and as a consequence reduced protein folding load on the ER. Another outcome
of eIF2α phosphorylation is the enhanced selective translation efficiency of ATF4, a
transcription factor which is involved in transcription of stress response genes.[69, 74, 75]
The release of BiP from ATF6 allows translocation of ATF6 from the ER membrane to
the Golgi.[67] In the Golgi, ATF6 undergoes cleavage by proteases S1P and S2P. Cleaved
ATF6 (p50) enters the nucleus and mediates the transcription of among others, ER
chaperones including BiP and ERAD proteins.[76-78] Expression of chaperones
increases the folding capacity of the ER while ERAD clears proteins that are not properly
folded. These are adaptation mechanisms that are designed to restore normal
homeostasis under acute ER stress as shown in the study where overexpressing the
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chaperone Bip protects the cells from death under conditions like oxidative stress or
hypoxia.[79]
Under chronic ER stress, UPR mediated adaptation is overwhelmed and cell death
pathways are activated by among others transcription factor C/EBP homologous protein
(CHOP).[80] CHOP also known as Gadd153 is a member of CCAAT/enhancer binding
protein family (C/EBP) and induces apoptosis by upregulating expression of proapoptotic
genes such as NOXA, and BIM to induce cell death. CHOP also mediates the decrease
of the anti-apoptotic protein BCL2 levels and increases the reactive oxygen species
leading to cytochrome c release from mitochondrial lumen initiating caspase 3/7
dependent apoptosis also known as the intrinsic pathway.[81] Role of CHOP in apoptosis
can be better understood with the study wherein the CHOP-/- mice treated with tunicamycin
(a small molecule UPR activator) showed resistance to kidney damage versus the wild
type.[82] While, CHOP activates the intrinsic pathway, use of several ER stress inducers
in studies have shown the activation of extrinsic pathway via caspase 8.[83] The bacterial
AB5 subtilase cytotoxin SubAB known to cleave the chaperone BiP and induce ER stress
upregulates CHOP and XBP1s in a dose-dependent manner. Studies have revealed that
under persistent ER stress (by treatment with ER stress inducers thapsigargin and
tunicamycin) the IRE1 activation is transient, whereas PERK signaling is maintained and
that artificially sustaining IRE1 activity enhances cell viability. Similarly, after 12 h of the
SubAB treatment spliced XBP1 levels decrease, whereas CHOP levels are increased
which activates the caspase-8 and caspase-3/7 activity. Similar results were obtained by
berefeldin-A (BfA) and thapsigargin treatment.[68, 84, 85] These suggest a role of
sustained ER stress, and interplay of PERK and IRE1 activation in determining the cell
fate. Additionally, PERK and IRE1 play opposing role in inducing cell death, with IRE1
playing more of an adaptive role. Another UPR mediated cell death is by activation of
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death receptor 5 (DR5). CHOP mediates transcription of DR5, whereas IRE1 transiently
catalyze DR5 mRNA decay, thus protecting from cell death. When faced with sustained
ER stress, DR5 protein levels increase leading to activation and subsequent caspase-8
mediated apoptosis.[84]
IRE1-TRAF2 is also shown to associate with proteolytically cleaving the caspase-12.
Caspase-12 proteolysis may be an indirect consequence of IRE1 activation involving
calpain activation by Ca2+ imbalance in the ER. Caspase-7 activation is also associated
with prolonged ER stress which mediates apoptosis by activating caspase-12.[86, 87]

UPR IN CANCER
Due to higher biomass requirements in tumors, UPR genes are upregulated to handle
higher folding needs. There is increasing evidence that UPR is activated in various tumors
including a range of breast cancer cell lines, glioblastoma and fibrosarcoma tumor models,
etc. Studies have indicated that BiP and XBP1 play an important role in facilitating tumor
progression.[88, 89] Stress induced by chemotherapy is also countered by UPR activation
in tumor cells. Although UPR has a protective role in tumors, UPR activators when
combined with other stressors can overcome the protective effects to induce cell death. A
recent study showed that pretreatment of tumor cells with UPR activators (tunicamycin
and DTT) helps cisplatin induce a caspase 12 dependent apoptotic cell death pathway.[90]
In response to ER stress, UPR activation attempts to mitigate, failing which the apoptotic
program is activated. There exists a therapeutic window with UPR activators as normal
cells have a higher adaptation window compared to cancer cells. This is assuming that
that the cancer cells and normal cells have similar adaptation threshold.
Various chemicals are known to induce ER stress mediated UPR activation in cells.
The well-described UPR activators are thapsigargin, tunicamycin, DTT and Brefedin A.
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Thapsigargin (Tg) is a sesquiterpene lactone isolated from plants that is a specific
sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) pump inhibitor. SERCA
pump is one of the major regulators of Ca2+homeostatsis within the cell. Ca2+ is a master
regulator for multiple signaling pathways and ER is a major Ca2+ store for the cell. The
SERCA pump is responsible for maintaining mM Ca2+ concentration in the ER.
Thapsigargin (Tg) blocks the SERCA resulting in depletion of ER Ca2+.[91, 92] This
activates UPR (ER stress response) inside the cell as high Ca2+ concentrations are
required for efficient folding by the chaperons.
Prostate cancer cells when treated with Tg show an initial dose-dependent increase
in Ca2+ from the baseline due to store-operated entry of extracellular Ca2+ in response to
ER Ca2+ depletion. This leads to increased CHOP and calmodulin expression, followed by
transient depletion and then subsequent robust secondary rise of Ca2+ leading to a
caspase-9 dependent irreversible commitment to apoptosis.[93, 94] Tg is shown to induce
UPR mediated apoptosis and cell death in the prostate and breast cancer cell lines. It
elevates the ATF4 and CHOP levels at low nM concentration at 6 hrs.[95] Tunicamycin
(Tm) is another ER stress inducer that blocks the N-glycosylation of the glycoproteins by
inhibiting

UDP-N-acetylglucosamine-dolichyl

phosphate

N-acetylglucosamine-1-

phosphate transferase (GPT). Cells treated with tunicamycin result in accumulation of
unfolded/misfolded proteins in the ER, thus activating ER stress mediated UPR.[96] The
binding of tunicamycin to GPT is irreversible and treatment with lower dosage or shorter
time results in adaptation or a lag period, whereas higher dosage and longer incubation
times results in cell cycle arrest and eventually apoptosis by robust upregulation of CHOP
and Gadd 34.[82, 97]
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Figure 2. Pictorial representation of the Unfolded Protein Response.
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NFκB and UPR
The NFκB pathway regulates the ER stress target genes as shown from study by Tam
and coworkers. They observed that there was reduction in thapsigargin (an ER stress
inducer) induced BiP/GRP78 expression in p65-deficient mouse embryonic fibroblasts
(MEF)s and found that p65 binds to the BiP promoter. [98] Conversely, ER stress is
involved in activation of the NFκB pathway.[99-101] In response to tunicamycin or
thapsigargin treatment IRE1 is autophosphorylated and binds to TNFα receptorassociated factor 2 (TRAF2) and recruits the IKK proteins. This triggers the
phosphorylation-degradation of IκBα and activates the NFκB pathway.[102] The ATF6 arm
of UPR activates NFκB pathway by phosphorylating Akt. Studies have shown that there
is crosstalk between BiP, Akt and NFκB pathway in prostate cancer cells.[103] AB5
subtilase cytotoxin SubAB which is known to cleave BiP activates all three arms of UPR.
But, SubAB is shown to induce ATF6 activation transiently which correlated with the
transient phosphorylation of Akt mediated activation of NFκB pathway.[104]
In response to stress, PERK functions as a binary switch. It regulates the expression
of anti-apoptotic proteins via the NFκB pathway to alleviate the stress failing which PERK
activates the transcription of CHOP to trigger cell death. PERK mediated activation of
NFκB doesn’t involve p65 dissociation from IκBα via the traditional phosphorylation by the
IKKβ and subsequent degradation of IκBα but simply by inhibiting the translation of the
IκBα protein.[99, 100] PERK mediated phosphorylation of eIF2α leads to the translational
inhibition of a wide range of proteins including IκBα and since IκBα has a short half-life,
p65 freely translocates to nucleus to mediate gene expression.[98] Since CHOP and NFκB
activation are required for opposing effects, from a therapeutic stand point activating
CHOP while inhibiting NFκB is beneficial.
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ER stress is involved in inducing NFκB pathway activation which results in antiapoptotic effects and inflammation.[105, 106] Conversely, studies have also suggested
that C/EBPβ transcription factors under stress conditions physically binds to p65 and
inhibits its activity.[107] This inhibition is mediated through the PERK and IRE1 arms of
the UPR. Under acute conditions ER stress induces NFκB pathway activation however
under chronic irremediable conditions (chronic ER stress) NFκB pathway is inhibited.
Nakajima and co-workers, showed that DHMEQ, an NFκB pathway inhibitor which is
known to be effective against hormone-insensitive prostate cancers and malignant breast
cancers, induced reactive oxygen species (ROS) generation and subsequently UPR.
Interestingly, they found that inhibiting UPR led to suppression of NFκB inhibition by
DHMEQ and that DHMEQ’s UPR-mediated NFκB inhibition is via expression of C/EBPβ
transcription factor.[51, 55, 108] The mechanism of the negative regulation of NFκB is also
by down-regulation of TRAF2 due to enhanced protein degradation.[102] To summarize
these reports emphasize the bidirectional regulatory role of ER stress on NFκB regulation.
As conventional NFκB inhibitors have limited clinical use because of their side effects and
limited effectiveness. The negative regulation of NFκB pathway by UPR further adds to
and supports the efficacy of developing NFκB pathway inhibitors that have the potential of
inducing the unfolded protein response.
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Figure 3. Interrelationship between UPR and NFκB, positive and negative regulation.
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CHAPTER 2: METHODS
General Chemistry Methods:
All reagents were purchased from commercial vendors and were used without further
purification. Flash chromatography was carried out on silica gel (200–400 mesh). Thin
layer chromatography (TLC) was run on pre-coated EMD silica gel 60 F254 plates and
observed under UV light at 254 nm and with potassium permanganate dip (put
composition in). Column chromatography was performed with silica gel (230-400 mesh,
grade 60, Fisher scientific, USA). 1H NMR (400 – 600 MHz) and 13C NMR (100 – 150 MHz)
spectra were done in (always put full form before formulas) CDCl 3 , DMSO-D 6 or CD 3 OD
on a Bruker instrument (CDCl 3 was 7.26 ppm for 1H and 77.00 ppm for
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C, DMSO-D 6

was 2.50 ppm for 1H and 39.00 ppm for 13C and CD 3 OD was 3.31 ppm for 1H and 49.3 for
13

C (why are you giving the ppm’s here when there is no mention of data in previous

analytical techniques. Be consistent). Proton and carbon chemical shifts were reported in
ppm relative to the signal from residual solvent proton and carbon. Preparative HPLC was
done on 250 x 21.2 mm C-18 column using gradient conditions (10 – 100% B, flow rate =
6.0 mL/min, 39 min). The eluents used were: solvent A (H 2 O with 0.1% Formic acid) and
solvent B (CH 3 CN with 0.1% Formic acid).
Chemical Inhibitors: All the inhibitors were synthesized in house by Dr. Sandeep Rana as
follows.

O
O
O

O

O

HO
O

O
N
H

O
N

O
N

O
N
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1-(prop-2-yn-1-yl)indoline-2,3-dione (2)
O
O
N

A solution of isatin (200 mg, 1.36 mmol) in anhydrous DMF (6 mL) was prepared and
cooled to 0°C under argon atmosphere. NaH (82 mg, 2.04 mmol) was added to the above
cooled mixture. After 10 min, propargyl bromide (0.19 mL, 2.04 mmol, 80%) was added,
and the solution was allowed to warm to ambient temperature and stirred for an additional
16h. The reaction mixture was washed with saturated NH 4 Cl and extracted with EtOAc.
The organic phase was washed with brine, separated, dried over MgSO 4 , and the solvent
was evaporated in vacuo. The crude residue was purified by silica gel chromatography to
afford the pure product (192 mg, 75%). 1H NMR(499 MHz, CDCl 3 ): 7.66 – 7.63 (m, 2H),
7.19 – 7.12 (m, 2H), 4.53 (d, J = 2.0 Hz, 2H), 2.30 (s, 1H).
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C NMR (126 Hz, CDCl 3 ):

182.49, 157.13, 149.59, 138.39, 125.44, 124.18, 117.68, 111.06, 75.65, 73.31, 29.43.
C 11 H 7 NO 2 [M]+: 185.05; found 186.27.
Methyl 2-((3-hydroxy-2-oxo-1-(prop-2-yn-1-yl)indolin-3-yl)methyl)acrylate

O
O
HO
O
N
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In a dry round bottom flask was taken 1-(prop-2-yn-1-yl)indoline-2,3-dione (40 mg, 0.22
mmol) and dissolved in 6:4 THF: water (2 mL) followed by addition of methyl 2(bromomethyl) acrylate (77 mg, 0.43 mmol) and indium powder (49 mg, 0.43 mmol).
Reaction mixture was stirred for 24h and progress of the reaction was monitored by thin
layer chromatography using 1:1 ethyl acetate:hexane. The reaction mixture was diluted
with ethyl acetate and washed with 0.1% HCl followed by washing with brine, and dried
using magnesium sulfate. Crude mixture was column chromatographed to obtain methyl
2-((3-hydroxy-2-oxo-1-(prop-2-yn-1-yl)indolin-3-yl)methyl)acrylate (33 mg, 54% yield). 1H
NMR (499 MHz, CDCl 3 ): 7.34 – 7.32 (m, 2H), 7.08 (t, J = 7.5 Hz, 1H), 7.03 (d, J = 8.0 Hz,
1H), 6.27 (s, 1H), 5.57 (s, 1H), 4.55 (dd, J = 2.5 Hz, 7.5 Hz, 1H), 4.35 (dd, J = 2.5 Hz, 7.5
Hz, 1H), 3.98 (br, 1H), 3.70 (s, 1H), 3.16 – 3.13 (m ,1 H), 2.76 – 2.73 (m, 1H), 2.24 – 2.23
(m, 1H).
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C NMR (126 MHz, CDCl 3 ): 176.46, 168.23, 141.16, 134.06, 130.18, 129.67,

129.25, 124.60, 123.02, 109.42, 75.77, 72.48, 52.28, 40.23, 29.30. C 16 H 15 NO 4 [M]+:
285.10; found 286.07.

4-methylene-1'-(prop-2-yn-1-yl)-3,4-dihydro-5H-spiro[furan-2,3'-indoline]-2',5-dione
(Analog 20)

O
O
O
N

Methyl 2-((3-hydroxy-2-oxo-1-(prop-2-yn-1-yl)indolin-3-yl)methyl)acrylate (33 mg, 0.12
mmol) was dissolved in 3 mL of DCM and cooled to 0º C. p-Toluene sulfonic acid (46 mg,
0.24 mmol) was added and the reaction mixture was stirred for 24h. Progress of the
reaction was monitored by thin layer chromatography. The crude mixture was diluted in
ethyl acetate, washed with brine, separated, dried over MgSO 4 , and purified on a column
to

yield

4-methylene-1'-(prop-2-yn-1-yl)-3,4-dihydro-5H-spiro[furan-2,3'-indoline]-2',5-
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dione (18 mg, 61% yield). 1H NMR (499 MHz, CDCl 3 ): 7.32 (dt, J = 7.5 Hz, 1 Hz, 1H),
7.34 (d, J = 7.0 Hz, 1H), 7.16 (dt, J = 7.5 Hz, 0.5 Hz, 1H), 7.11 (d, J = 8.0 Hz, 1H), 6.42 (t,
J = 2.5 Hz, 1H), 5.81 (t, J = 2.5 Hz, 1H), 4.59 – 4.38 (m, 2H), 4.35 (dd, J = 2.5 Hz, 7.5 Hz,
1H), 3.45 – 3.10 (m, 2H), 2.28 (t, J = 2.5 Hz, 1H). 13C NMR (126 MHz, 126 MHz): 172.57,
168.77, 141.99, 132.52, 131.26, 126.53, 124.24, 124.03, 123.33, 110.04, 79.24, 75.99,
73.09, 36.32, 29.64

Conditions:

(i).

1,n-dibromoalkane,

NaH,

DMF,

RT,

O/N;

(ii).

Methyl

2-

(bromomethyl)acrylate, In, THF: water, RT, 24h (40-70%); (iii). TsOH, DCM, RT, 24h (6080%).
Step i: In a dry round bottom flask isatin (1 eq.) was dissolved in dry DMF and the reaction
mixture was cooled to 0°C. NaH (0.45 eq.) was added and the reaction mixture was stirred
for 15 minutes followed by the addition of 1,n-dibromoalkane (0.45 eq). The reaction was
warmed to room temperature and stirred at room temperature for 24h. The crude mixture
was diluted in ethyl acetate and washed with ammonium chloride and brine. The organic
layer was separated and dried over magnesium sulfate, filtered, and evaporated to give
pure solid.
Step ii: In a dry round bottom flask isatin (1 eq.) was dissolved in 6:4 THF: Water. Indium
metal powder (2.2 eq.) was then added and the reaction mixture was stirred for 10
minutes. Methyl 2-(bromomethyl) acrylate (2.2 eq.) was added to the above mixture and
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the reaction was stirred for 24h. Progress of the reaction was monitored by TLC using
70% ethyl acetate in hexane solvent. Upon completion, the reaction mixture was diluted
with ethyl acetate and washed with 0.1% HCl followed by brine. The organic layer was
separated and dried using magnesium sulfate. The crude mixture was purified on a
column using a hexane-ethyl acetate gradient to obtain the acyclic compound.
Step iii: The acyclic compound (1 eq.) from step ii was taken in round bottom flask,
dissolved in dry dichloromethane and the reaction mixture was cooled to 0°C. p-Toluene
sulfonic acid monohydrate salt (2.2 eq.) was added and the reaction mixture was stirred
at room temperature for 12 h under inert atmosphere. Progress of the reaction was
monitored by TLC. The crude mixture was washed with brine and extracted using
dichloromethane and dried over magnesium sulfate. It was purified on a column using a
hexane-ethyl acetate gradient to obtain the desired product as white solid.
36-286 (n3)
H NMR (499 MHz, CDCl 3 ) δ 7.41 (d, J = 8.4 Hz, 1H), 7.41 – 7.35 (m, 1H), 7.35 (dd, J =

1

7.5, 3.6 Hz, 2H), 7.14 (t, J = 7.6 Hz, 2H), 6.86 (dd, J = 17.5, 7.9 Hz, 2H), 6.42 (q, J = 3.0
Hz, 2H), 5.82 (t, J = 2.5 Hz, 2H), 4.14 (q, J = 7.1 Hz, 1H), 3.79 (td, J = 7.1, 4.6 Hz, 4H),
3.38 (dt, J = 17.4, 2.4 Hz, 1H), 3.27 (dt, J = 17.2, 2.5 Hz, 1H), 3.17 – 3.11 (m, 1H), 3.14 –
3.07 (m, 1H), 2.17 (dt, J = 17.7, 7.3 Hz, 2H), 2.06 (s, 1H), 1.28 (t, J = 7.2 Hz, 1H).
C NMR (126 MHz, CDCl 3 ) δ 173.73, 173.59, 168.96, 168.86, 142.72, 142.66, 132.78,
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132.66, 131.44, 131.41, 126.71, 126.69, 124.49, 124.47, 123.80, 123.20, 123.10, 109.05,
109.02, 79.32, 79.20, 77.25, 77.00, 76.75, 60.36, 37.96, 37.51, 36.17, 36.13, 25.18, 24.76,
21.01, 14.17. C 27 H 22 N 2 O 6 [M]+: 470.48; found 493.06 (M + Na).
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36-252 (n7)
H NMR (499 MHz, CDCl 3 ) δ 7.38 (td, J = 7.9, 3.1 Hz, 2H), 7.31 (d, J = 7.4 Hz, 2H), 7.10

1

(t, J = 7.6 Hz, 2H), 6.87 (dd, J = 7.9, 3.5 Hz, 2H), 6.40 (q, J = 2.9 Hz, 2H), 5.80 (dt, J =
5.3, 2.6 Hz, 2H), 3.75 – 3.58 (m, 4H), 3.29 (ddt, J = 17.2, 5.0, 2.5 Hz, 2H), 1.67 (t, J = 7.4
Hz, 5H), 3.10 (dt, J = 17.3, 2.9 Hz, 2H), 1.35 (d, J = 9.8 Hz, 7H).
C NMR (126 MHz, CDCl 3 ) δ 173.43, 169.02, 143.32, 132.85, 131.26, 126.81, 124.30,
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123.44, 123.07, 109.24, 79.30, 77.26, 77.00, 76.75, 40.16, 36.29, 28.64, 27.02, 26.52.
C 31 H 30 N 2 O 6 [M]+: 526.59; found 549.59 (M + Na).
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36-242 (n12)
H NMR (499 MHz, CDCl 3 ) δ 7.38 (t, J = 7.8 Hz, 2H), 7.31 (d, J = 7.5 Hz, 2H), 7.10 (t, J =

1

7.6 Hz, 2H), 6.88 (d, J = 7.9 Hz, 2H), 6.40 (d, J = 3.0 Hz, 2H), 5.79 (q, J = 2.1 Hz, 2H),
3.66 (hept, J = 7.0 Hz, 4H), 3.29 (dt, J = 17.2, 2.5 Hz, 2H), 3.10 (dt, J = 17.2, 2.8 Hz, 2H),
2.04 (s, 1H), 1.68 (q, J = 7.3 Hz, 4H), 1.32 (s, 10H), 1.25 (dd, J = 12.6, 5.1 Hz, 9H).
C NMR (126 MHz, CDCl 3 ) δ 173.36, 169.01, 143.40, 132.87, 131.19, 126.85, 124.27,
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123.38, 123.01, 109.22, 79.29, 77.26, 77.00, 76.75, 40.34, 36.32, 29.41, 29.35, 29.14,
27.16, 26.76. C 36 H 40 N 2 O 6 [M]+: 596.72; found 919.70 (M + Na).

29
36-242-1H.30.fid
36-242-1H

4500

4000

3500

3000

2500

2000

1500

1000

500

0

0.0

9.5

9.0

8.5

8.0

7.5

7.0

6.5

6.0

5.5

5.0
f1 (ppm)

4.5

4.0

3.5

3.0

2.5

2.0

1.5

1.0

0.5

0.0

30
1600

36-242-C3-1H.11.fid
36-242-c3-C

1500
1400
1300
1200
1100
1000
900
800
700
600
500
400
300
200
100
0
-100

210

200

190

180

170

160

150

140

130

120

110

100
90
f1 (ppm)

80

70

60

50

40

30

20

10

0

-10

QUATTROZQ
N=12 17 (0.294) Cm (2:18)

Scan ES+
1.88e7

78.86

100

79.12

100.89
101.08

101.28

%

79.31

619.70

179.15
651.58
156.91
635.71
80.87

102.84

132.93

697.56

0

m/z
20

40

60

80

100

120

140

160

180

200

220

240

260

280

300

320

340

360

380

400

420

440

460

480

500

520

540

560

580

600

620

640

660

680

700

720

31

40-237
O

O
Cl

Cl

N
H

N
H

Potassium carbonate (4.79 g, 34.65 mmol) was added to a cooled (0 ⁰C) stirring solution
of octane-1,8-diamine (2g, 13.86 mmol) in a mixture of dichloromethane(15 mL) and water
(10 mL). Chloroacetyl chloride (3.13 g, 27.72 mmol) in DCM (10 mL) was added dropwise
to the above mixture with constant stirring. The reaction mixture was stirred overnight at
room temperature and evaporated to dryness under vacuum. Cold water was added to
the above and the reaction mixture was filtered to yield (3.7g) of N,N'-(heptane-1,7diyl)bis(2-chloroacetamide) as white solid.
H NMR (499 MHz, DMSO-d 6 ) δ 8.17 (t, J = 5.7 Hz, 2H), 4.02 (s, 4H), 3.06 (q, J = 6.6 Hz,

1

4H), 1.40 (p, J = 6.7 Hz, 5H), 1.25 (broad s, 9H).
C NMR (126 MHz, DMSO-d 6 ) δ 165.12, 42.12, 39.48, 39.31, 39.14, 38.98, 38.81, 38.64,
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38.48, 38.34, 28.25, 28.06, 25.68.
40-242
O
I

O
N
H

N
H

I

N,N'-(heptane-1,7-diyl)bis(2-chloroacetamide) (220 mg, 0.74 mmol) was dissolved in
acetone (7 mL) followed by addition of sodium iodide (333 mg, 2.22 mmol). Reaction
mixture was refluxed overnight and solvent was evaporated to dryness. Dichloromethane
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was added to crude mixture and washed with 5% sodium bisulfite and brine. Solvent was
removed under vacuum to yield N,N'-(heptane-1,7-diyl)bis(2-iodoacetamide).
H NMR (499 MHz, DMSO-d 6 ) δ 8.27 (s, 2H), 4.03 (s, 4H), 3.05 (q, J = 6.6 Hz, 4H), 2.53

1

– 2.47 (m, 3H), 1.39 (p, J = 6.6 Hz, 5H), 1.24 (s, 10H).
C NMR (126 MHz, DMSO-d 6 ) δ 165.18, 42.15, 39.50, 39.33, 39.16, 39.00, 38.83, 38.66,
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38.49, 38.34, 28.25, 28.06, 25.70.
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Figure 4. A) NMR spectrum of analog 19. B) NMR spectrum of dimer n7. Compared to
the monomer 19 we see additional aliphatic signals (1.0-2.0 ppm) which correspond to
the linker. The CH2 signals (3.0 – 4.0 ppm) in the α-methylene-γ-butyrolactone are
doubled in the dimer n7 when compared to the monomer 19.
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MS study with recombinant p65, IKKβ with analog 19:
The proteins used – 5 µL of pure IKKβ (MW ~ 83979) 2.5 mg/mL in 25 mM Tris-HCl,
pH 8.0, 150mM sodium chloride [NaCl], 1mM dithiothreitol [DTT]) and 5 µL of pure p65
(MW ~ 37044) 1.5mg/mL in 25 mM Tris-HCl, pH 8.0, 150mM NaCl, 1mM DTT), were
centrifuged at 14,000 rpm at 4°C for 10 minutes. The reaction was performed by addition
of 0.5 µL of DMSO or analog 19 (prepared by dissolving 11 µL of 10mM analog 19 in 89
µL buffer. Buffer composition: 1.1 mM in Tris-HCl, pH 7.6, 100mM NaCl, 1mM DTT, 2 mM
MgCl 2 , 1% Triton X-100) to 5 µL of pure IKKβ or p65. A control was also included with the
addition of 0.5 µL of DMSO instead of analog 19. The samples were vortexed for 30
seconds and submitted to the UNMC Mass spectrometry core facility for MS/MS analysis.
(Figure 1A)
A 1 µg sample of the IKKβ and p65 was trypsin/ chymotrypsin digested and analyzed
by mass spectrometry. The digested peptides were re-suspended in 2% acetonitrile (ACN)
and 0.1% formic acid (FA) and loaded onto trap column Acclaim PepMap 100 75µm x 2
cm C18 LC Columns (Thermo Scientific™) at flow rate of 4 µl/min and then separated with
a Thermo RSLC Ultimate 3000 (Thermo Scientific™) on a Thermo Easy-Spray PepMap
RSLC C18 75µm x 50cm C-18 2 µm column (Thermo Scientific™) with a step gradient of
4–25% solvent B (0.1% FA in 80 % ACN) from 10-57 min and 25–45% solvent B for 57–
62 min at 300 nL/min at 50°C with a 90 min total run time. The eluted peptides were
analyzed by a Thermo Orbitrap Fusion Lumos Tribrid (Thermo Scientific™) mass
spectrometer in a data dependent acquisition mode. A survey full scan MS (from m/z
350–1800) was acquired in the Orbitrap with a resolution of 120,000. The automatic gain
control (AGC) target for MS1 was set as 4 × 105 and ion filling time set as 100 ms. The
most intense ions with charge state 2-6 were isolated in 3 s cycle and fragmented using
higher-energy collisional dissociation (HCD) fragmentation with 40 % normalized collision
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energy and detected at a mass resolution of 30,000 at 200 m/z. The AGC target for MS/MS
was set as 5 × 104 and ion filling time set 60 ms dynamic exclusion was set for 30 s with a
10-ppm mass window. Protein identification was performed by searching MS/MS data
against the Swiss-prot human protein database downloaded on Aug 20, 2018. The search
was set up for full tryptic peptides with a maximum of two missed cleavage sites.
Acetylation of protein N-terminus and oxidized methionine were included as variable
modifications and carbamidomethylation of cysteine was set as fixed modification. The
precursor mass tolerance threshold was set for 10 ppm and maximum fragment mass
error was 0.02 Da. Qualitative analysis was performed using PEAKS 8.5 software. The
significance threshold of the ion score was calculated based on a false discovery rate of
≤ 1%.

Cell lines and culture conditions:
Non-transformed hTERT-immortalized human fallopian tube epithelial cells (FT282C11), human ovarian cancer cell lines (OVCAR5, OVCAR8, CaOV3), human embryonic
kidney cells (HEK293), non-transformed hTERT-immortalized human pancreatic nestin
expressing cells (HPNE) and human pancreatic cancer cell lines (MiaPaCa2 and S2013)
were cultured in Dulbecco’s modified Eagle’s medium high glucose (DMEM, HyClone
#SH30022.01) supplemented with 10% fetal bovine serum (FBS, Gibco # 26140079) and
1% Penicillin-streptomycin (Penstrep, Hyclone # VBV109). Human ovarian cancer cell
lines (A2780, OVCAR4, KURAMOCHI, SNU-119) were cultured in Roswell Park Memorial
Institute-1640 medium (RPMI, HyClone #SH30027.01) supplemented with 10% FBS and
1% Penstrep. Human lung cancer cell line luciferase (A549) was cultured in DMEM high
supplemented with 10% FBS, 1% Penstrep and 100 µg/ml hygromycin B.
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Western Blot Analyses:
Cells were washed with cold 1X PBS and scraped before being lysed in a buffer
comprised of Radioimmunoprecipitation assay (RIPA) buffer (Thermo Scientific), sodium
orthovandate (Na 3 VO 4 , Sigma), sodium flouride (NaF, Sigma), β-glycerophosphate
(Sigma) and 1mM phenylmethylsulfonyl fluoride (PMSF, Sigma). The samples were
incubated on ice for 30 minutes and vortexed at 15-minute intervals. The lysed samples
were centrifuged at 14,000 g for 10 minutes at 4°C and the supernatant was collected.
Protein quantification was determined using the BCA Protein Assay kit (Pierce #23225).
20 - 40µg of total protein was loaded per well and run on a 4-15% gradient gel (Bio-Rad)
in 1X TRIS-Glycine-SDS Buffer (Research Products International Corporation #T32080)
at 110V for ~80 minutes and separated by SDS-PAGE (sodium dodecyl sulfatepolyacrylamide gel). The proteins were transferred to a polyvinylidene fluoride (PVDF)
membrane by semi-dry transfer method (ThermoScientific #35035), (18V for ~35
minutes). The membranes were blocked by shaking in a solution of 5% (w/v) non-fat dry
milk in 1X-Tris Buffered Saline with 0.1% Tween (1X TBS-T) for 1 hour at room
temperature. The membranes were then incubated with the primary antibodies, which
were diluted in 5% milk in 1XTBST, at 4°C overnight with gentle rocking. After a wash with
1X TBST (3X for 10 minutes each), the membranes were incubated with the appropriate
HRP-conjugated secondary antibody for 1 hour at room temperature with gentle rocking.
The membranes were then washed again (3X for 10 minutes each) with 1X TBST. The
membranes were then incubated with ECL Prime (GE Healthcare #RPN2236) to detect
protein levels. ImageJ was used for the quantification of the western blots. Western blot
experiments were performed in triplicates, unless otherwise noted.
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Antibodies:
p65, Santa Cruz #sc-372; IκBα, CST #4812; IKKβ, CST # 8943; IKKγ, Millipore # 05631; Hsp90, CST #4877; p-IκBα, CST #9246; HDAC1, CST #5356; α-tubulin, CST #3873;
Cl-PARP, CST #9541; IKKα, Santa Cruz #sc-52932; PARP, CST #9542; Histone H3, CST
#4499; His tag, #2366; XBP1, Abcam #Ab198999; ATF6, CST #65880; pS51-eIF2α, CST
#3398; eIF2α, CST #5324; Cl-Caspase-7, CST #8438; Bip, CST #3177; PERK, CST
#5683; CHOP, CST #2895; IRE1, CST #3294.

Click chemistry and Pulldown:
A2780 cells were allowed to grow to 90% confluency in a 10 cm flask under normoxic
conditions at 37 °C in a humidified CO 2 incubator. The cells were treated with 20 µM of
Analog 20 for 1h. After incubation, the medium was removed, and the cells were washed
with cold PBS. The cells were then dissociated from the flask using cell scraper. The cells
were collected in 1X PBS (8 mL) and centrifuged (1000 rpm, 5 min) in a conical tube. The
cells were washed again with cold 1X PBS (10 mL) and centrifuged. The cells were lysed
by using the lysis method previously mentioned. The lysates were centrifuged at 14,000
g for 10 min and supernatant was collected. The lysates were stored at −80 °C until further
use.
500 µg - 1mg of the thawed lysate was transferred to clean Eppendorf tubes. 200 μL
of 10 w/v% SDS in ddH2O was added and the solution was heated to 65°C for 10 min.
Click reagents (10 μL copper sulphate, 100 mM stock in ddH2O; 20 μL TBTA, 20 mM
stock in DMSO; 20 μL Biotin-N3 [Sigma-Aldrich #762024], 20 mM stock in DMSO; 10 μL
TCEP, 100 mM in ddH2O) were added and the reaction was allowed to proceed for 3 hrs
at RT. 15 μL of this biotinylated sample was saved as the input lysate control.
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The remaining sample was then separated on a monomeric avidin column according
to the manufacturer’s instructions (Pierce) at 4°C. The samples were eluted using the
regeneration buffer (0.1 M HCl glycine, pH 2.8). The eluted samples were concentrated
using a 10 kDa molecular weight cutoff filter (Amicon). ddH2O (50 mL) was and the
samples were concentrated to ∼500 μL. The concentrated samples were evaporated to

dryness in a SpeedVac for 10 hrs at RT. The lyophilized samples were then dissolved in

PBS (25 μL) and 6X sample loading dye was added (5 μL, Thermo Scientific) and
vortexed. The input lysate control was also treated in a similar fashion. All samples were
heated to 90°C for 5 min and subjected to SDS-PAGE as mentioned above. After PAGE
the proteins were transferred to PVDF membranes and were incubated with the respective
primary antibodies (p65, Santa Cruz #sc-372; IκBα, CST #4812; IKKβ, CST # 8943; IKKγ,
Millipore # 05-631) at a 1:1000 dilution in 0.5% nonfat milk (Bio-Rad) in 1X TBST (10 mL)
overnight at 4°C. The secondary HRP-conjugated antibodies (anti-rabbit poly-HRP, Pierce
#32260; anti-mouse poly-HRP, Novex #A16072) were added at a 1:5000 dilution in 5%
nonfat milk (Bio-Rad) in 1X TBST (10 mL) for 1 h at RT.

CRISPR knockout OVCAR5 and MiaPaCa2 lines
For generating the OVCAR5 p65 knockout, 2 x 105 OVCAR5 cells were seeded in 60
mm dishes and incubated overnight at 37°C in a humidified CO 2 incubator. For the first
round of transduction, transduction media was prepared by adding 4 µg/ml of polybrene
and the Edit-R lentiviral hEF1α-Blast-cas9 nuclease particles (Dharmacon, #VCAS10126)
at a MOI (V= MOI x CN/VT x 1000; where V is volume of lentiviral stock in µl, MOI is
desired multiplicity of infection, CN is number of cells at transduction and VT is lentiviral
titer in TU/ml) of 0.3 to serum free Opti-MEM (Gibco) growth media. To each plate, 2 mL
of transduction media was added and incubated for 4 hrs at 37°C in a humidified CO 2
incubator. After 4 hrs, 4 mL of complete DMEM growth media was added to the plates and
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the cells were allowed to grow for an additional 24 hrs. The media was replaced with
growth media containing 6 µg/ml of blasticidin for selection of the transduced cells. An
OVCAR5 plate which was not transduced was treated with the selection media, to serve
as a control plate. After 4 days the transduced plate was 80% confluent whereas the
control plate was ~5% confluent. The cas9 expressing cells were selected for 10-15 days
and subsequently frozen stocks were prepared. For the second round of transduction,
OVCAR5-cas9 expressing cells were seeded at a density of 2 x 105 cells in 60 mm dishes
and incubated overnight at 37°C in a humidified CO 2 incubator. Transduction media was
prepared by adding 4 µg/ml of polybrene and the Edit-R predesigned human lentiviral
RELA sgRNA (Dharmacon, #VSGH10142-246501407) at a MOI of 0.3 to the serum free
growth media. To each plate 2 mL of transduction media was added and incubated for 4
hrs at 37°C in a humidified CO 2 incubator. After 4 hrs, 4 mL of the complete growth media
was added to the plates and the cells were allowed to grow for an additional 24 hrs. The
media was replaced with growth media containing 2 µg/ml of puromycin for selection of
the transduced cells. An OVCAR5 plate which was not transduced was also treated with
the selection media to serve as a control plate. The knock-out cells were selected for 1015 days before frozen stocks and lysates were prepared for validation by western blotting
(Figure 5A).
MiaPaCa2 IKKβ knockout cell line was a kind gift from Dr. Eric Kmiec from Genome
Editing Institute, University of Delaware (cell line generated by Pawel Bialk). The cell line
was generated by ssDNA insertion with CRISPR/cas9 Ribonucleoprotein.[109] The
lysates were prepared for validation by western blotting (Figure 5B).
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Figure 5. A) Western blot analysis of OVCAR5 and OVCAR5 p65 knock out lines. B)
Western blot analysis of MiaPaCa2 and MiaPaCa2 IKKβ knock out lines.
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TNFα induced NFκB luciferase reporter assay:
A549 luciferase cells were seeded in white-walled 96-well plate at a density of 50,000
cells/well and incubated overnight at 37°C, 5% CO 2 . The cells were treated the next day
with varying concentrations of dimer (n3, n7 and n12) for 2 hrs. Afterwards, the cells were
stimulated with 20 ng/ml of TNFα for 3 hrs followed by addition of Alamar Blue (Bio-Rad,
#BUFO12B). The cells were incubated for 3 more hrs and the fluorescence (560 ex /590 em )
was measured on the SpectraMax M5 e reader at the bottom-read setting. The plates were
cooled to RT for 15 min and 110 μL of ONE-Glo Luciferase reagent (Promega, #E6120)
was added to each well and incubated at RT in the dark for 10 min. Luminescence was
read at 1000ms integration on the SpectraMax M5 e plate reader.

Cytoplasmic and nuclear fraction extraction:
Briefly, 2 x 106 OVCAR5 cells were seeded in 10-cm dishes and allowed to adhere
overnight at 37°C and 5% CO 2 . Next day, the cells were treated with indicated
concentrations of the inhibitors and incubated for 2 hrs. They were then stimulated with
40 ng/ml of TNFα for 10 min. To extract the cytoplasmic protein fraction, the cells were
washed with ice-cold 1X PBS, dislodged with cell scraper, resuspended in PBS and spin
down in 15 mL Eppendorf tubes. The supernatant was discarded, and the cell pellet was
resuspended in ~120 µl of cell lysis buffer A (10 mM HEPES; pH 7.5, 0.1 mM
ethylenediaminetetraacetic acid [EDTA], 10 mM potassium chloride [KCl], 1 mM
Dithiothreitol [DTT], 0.5 mM phenylmethylsulfonyl fluoride [PMSF], 0.5 % Nonidet-40) and
1X protease inhibitor cocktail (). The cells were incubated on ice for 30 min with mild
intermittent vortexing every 10 min. The samples were then centrifuged at 12,000 g for 10
min at 4°C. The supernatant (cytoplasmic fraction) was collected, and stored at -80 °C.
Next the pellet was washed two times with the cell lysis buffer A and centrifuged at 12,000
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g for 2 mins each at 4°C. The pellet was then resuspended in 80 µl of nuclear extraction
buffer B (20 mM HEPES; pH 7.5, 1 mM EDTA, 40 mM NaCl, 1 mM DTT, 1 mM PMSF)
and 1X protease inhibitor cocktail. The cells were incubated on ice for 40 min with mild
intermittent vortexing every 10 mins. The samples were then centrifuged at 12,000 g for
15 min at 4°C. The supernatant (nuclear fraction) was collected, and stored at -80 °C.[110,
111] The lysates were quantified using the BCA assay kit (Pierce #23225) and 40 µg of
total protein was used for SDS-PAGE followed by western blotting as mentioned above.

Reaction of recombinant p65 and IKKβ with Analog 19, dimers n3, n7
and 40-242:
Both p65 and IKKβ proteins were generated by Dr. Tom Huxford’s lab (Department of
Chemistry & Biochemistry, San Diego State University). The human IKKβ protein has two
residues, Ser177 and Ser181, mutated to Glu and an N-terminal hexa-histidine tag. The
murine p65 protein is comprised of 1-325 amino acid residues from the N-terminus. The
reactions were set up in six 0.2 ml tubes with 7.72 µM protein in a reaction volume of 2.1
µL. The first two tubes had 7.72 µM of either p65 or IKKβ alone respectively. The
remaining tubes had equimolar concentrations (7.72 µM) of the protein and the dimer (n3,
n7), analog 19 or 40-242. The reaction mixture was slightly vortexed, spun down and
incubated at 4°C for 24 hrs. The next day, the reaction was stopped by adding loading dye
to each tube. The samples were subjected to SDS-PAGE followed by western blotting and
silver staining. For western blotting the membranes were probed for p65 using the
antibody against N-terminal since the protein is truncated at the C-terminal (Santa Cruz,
#sc8008) and for IKKβ using antibody against His-tag since the protein had an N-terminal
His-tag (CST, #2366).
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Silver staining:
For silver staining, the protocol posted on Rockefeller University’s Proteomics
resource center site was used. After SDS-PAGE, the gel was fixed in 50% methanol and
5% acetic acid for 20 min. This was followed by a wash in 50% methanol for 10 min and
water for 10 min. Then the gel was incubated with 0.02% sodium thiosulfate (SigmaAldrich) solution for 1 min (to sensitize) followed by 2X washes with water for 1 min each.
For the next step the gel was incubated for 20 min with a 0.1% silver nitrate (SigmaAldrich, # 209139) in 0.08% formalin (37%) solution (Sigma). This was followed by 2X
washes with water for 1 min each. The gel was then developed by incubating with a 2%
sodium carbonate in 0.04% formalin (37%) solution. The solution was replaced if it turned
yellow until the required intensity of protein bands was obtained. Finally, the reaction was
stopped by incubating the gel with 5% acetic acid for 10 min followed by a 5 min water
wash.

Cell Viability assay:
Cancer cells were plated at a density of 4,000 cells/well in a clear, sterile 96-well plate
and allowed to adhere overnight at 37°C, 5% CO 2 . The following day, the cells were
treated with indicated concentrations (3-fold dilutions starting at 10 µM) of inhibitors Analog 19 and dimers (n3, n7 and n12). PrestoBlue cell viability (10 µL) reagent
(Invitrogen, #A13262) was added to cells after 72 hrs drug incubation and incubated for
15 min at 37 °C. Fluorescence (560 ex /590 em ) was measured using the SpectraMax M5e
instrument to assess the growth inhibition. Percentage growth inhibition was calculated
using the formula
100-[100*(Samples-T 0 )/(T 100 -T 0 )]
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T 0 is the vehicle control reading immediately following drug addition and T 100 is the vehicle
control reading at the end of the 72-hr incubation.

NCI 60 screening:
Analog 19 and dimer n3 were screened against the NCI 60 cancer cell panel by the
Developmental Therapeutics Program (DTP) at National Institute of Health (NIH). The GI 50
values were obtained from a sulphorhodamine B assay of total protein, using 5-doses of
inhibitors

treated

for
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hrs

as

described

in

detail

at

http://dtp.nci.nih.gov/branches/btb/ivclsp.html.[112]

Caspase 3/7 assay:
Ovarian cancer cells were plated at density of 4,000 cells/well in a white, clear bottom
sterile 96-well plate and incubated overnight at 37°C, 5% CO 2 . The following day, the cells
were treated with 1 µM n7 dimer and incubated for 6 hrs. 10 µL Presto Blue cell viability
reagent was added to each well and incubated for 15 min. The fluorescence (560 ex /590 em )
was measured on the SpectraMax M5e with a bottom-read setting. The plate was cooled
to room temperature for 15 min and 110 μL of Caspase-Glo-3/7 reagent (Promega,
#G8093) was added to each well and incubated at room temperature (RT) for 1 hr.
Luminescence was read at 1000ms integration on the SpectraMax M5e plate reader.

RNA isolation:
OVCAR5 cells were seeded at a density of 2 x 106 cells in 100-mm dishes and allowed
to adhere overnight. The following day, cells were treated with 10 µM of n7 for 2, 6 and
12 hrs followed by 20ng/ml of TNFα stimulation for 30 min post-treatment. All the
subsequent steps were performed at room temperature (RT). The cells were washed with
PBS post-treatment and incubated for 5 min at RT on shaker with 2 mL of Trizol
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(Invitrogen, #15596018). The samples were harvested and collected in microfuge tubes
(1 ml per 2 ml-tube). RNA purification steps were performed using the Direct-zol Miniprep
Plus kit (Zymo Research, #R2070) according to the manufacturer’s protocol. Equal volume
of ethanol was added to the tubes and vortexed mildly. The mixture was transferred to the
Zymo-spin IIICG columns in collection tubes and centrifuged. All the centrifugation steps
were done at 16,000g for 30 seconds unless otherwise indicated. The flow-through was
discarded and the columns transferred to new collection tubes. The columns were then
washed with 400 µL of RNA wash buffer and centrifuged. Following the wash, 5 µL of
DNase I and 75 µl of DNA digestion buffer mix was added to the columns and incubated
for 15 min at RT. The columns were then washed by adding 440 µL of Direct-zol RNA
Prewash and centrifuged. The flow-through was discarded and the wash step was
repeated. Next, 700 µL of RNA wash buffer was added to the column and centrifuged for
2 min. The columns were then transferred to RNase-free tubes and 50 µL of
DNase/RNase free water was added to the column matrix to elute out the RNA.

RNA-seq Analysis:
RNA-seq analysis was performed at the UNMC Genomics Core Facility. The samples
were analyzed for purity and the concentration was assessed by measuring the A 260/280
ratio using the Nanodrop (Thermo Scientific, Nanodrop Products, Wilmington, DE)
instrument. Samples with A 260/280 ratio values of 1.8 - 2.0 were used for further processing.
To test for integrity, 200 ng of the RNA was analyzed with a Fragment Analyzer (Advanced
Analytical Technical Instruments, Ames, IA). Next, sequencing libraries were generated
by the UNMC NGS Core beginning with 1 µg of total RNA from each sample using the
TruSeq V2 RNA sequencing library kit from Illumina following recommended procedures
(Illumina Inc., San Diego, CA). Resultant libraries were assessed for size of insert by
analysis of an aliquot of each library on a Bioanalyzer instrument (Agilent Technologies,
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Santa Clara, CA). Each library had a unique indexing identifier barcode allowing the
individual libraries to be multiplexed together for efficient sequencing. Multiplexed libraries
(12 samples per pool) were sequenced across 2 lanes of the HiSeq 2500 DNA Analyzer
(Illumina) to generate a total of approximately 20 to 25 million 50 bp single reads for each
sample. The quality of the sequencing was continually monitored with regards to the
cluster number, fluorescence intensity and percentages of reads passing filter with a Q30
score. Following sequencing, the samples were de-multiplexed to produce FASTQ files.
The resulting sequence files were processed by the UNMC Epigenomics core facility.
Adaptor sequences and low quality (Phred score: 20) ends were trimmed using the Trim
Galore

software

package

(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). The resulting FASTQ
files were aligned to the human genome (GRCm38/mm10) using the software TopHat
(v2.0.8) (http://ccb.jhu.edu/sofware/tophat/index.shtml). The software Cufflinks (v2.1.1)
(http://cole-trapnell-lab.github.io/cufflinks/) was used to estimate the expression values,
and Cuffdiff (v2.1.1) was used to determine the differential expression.

Proteomics analysis
The TMT10plex mass tag labelling kit and reagents (Thermo Scientific, #90406) were
used and the manufacturer’s protocol was used the labelling of peptides. The pierce high
pH reversed-phase peptide fractionation kit (Thermo Scientific, #84868) was used for the
fractionation steps according to the manufacturer’s protocol. Briefly, OVCAR5 cells were
seeded at a density of 2 x 106 cells in 100-mm dishes and allowed to adhere overnight.
The following day, the cells were treated with 10 µM of the dimer n7 for 2, 6, and 12 hrs.
Cells were harvested and lysed by adding 100μL of NETN (NaCl, EDTA, Tris-Cl, Nonidet
P-40), 10 μL/mL of Protease inhibitor, 30 μL/mL of 1.6 M NaF, 25 μL/mL of 1 M βglycerophosphate and 2 μL/mL of 50 mM Na 3 VO 4 per sample. Lysates were centrifuged
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at 16,000 g for 10 min at 4°C. The supernatant was removed, and the protein
concentration was estimated using the BCA kit. Next, 100 μg of protein per condition was
transferred into new tubes and the final volume was adjusted to 100 μL with 100 mM
triethylammonium bicarbonate (TEAB, pH 7-8). 5 μL of 200 reducing agent (TCEP) was
added to break the disulfide bonds and the samples were incubated at 55°C for 1 hr. 9 mg
of iodoacetamide was dissolved with 132 μL of 100 mM TEAB to make a 375 mM
iodoacetamide solution immediately before use. 5 μL of the 375 mM iodoacetamide was
added to the samples and incubated for 30 minutes in dark at RT. Six volumes (~600 μL)
of pre-chilled (-20°C) acetone was added to the mixture and allowed to precipitate
overnight. The samples were centrifuged at 8000 g for 10 min at 4°C, the supernatant was
carefully removed, and the pellet was air dried for 2-3 min. 100 μg of acetone-precipitated
(or lyophilized) protein pellets were resuspended in 100 μL of TEAB. Fresh trypsin solution
was prepared and 2.5 μL of trypsin (i.e., 2.5 μg per 100 μg of protein) was added to the
samples and digested overnight at 37°C. Next, the peptides were quantified using pierce
quantitative colorimetric peptide assay (Thermo Scientific, #23275) according to the
manufacturers protocol followed by peptide labeling. The TMT label reagent was
equilibrated to RT and the 5 mg vial was dissolved in 256 μL of anhydrous acetonitrile with
intermittent vortexing for 5 min. TMT labeling reagent (41 μL) was added to 100 μL sample
(25 – 100 μg protein digest) and the reaction was incubated at RT for 1 hr. To quench the
reaction, 8 μL of 5% hydroxylamine was added and incubated for 15 min at RT. Next, 10
– 100 μg of the digested sample was dissolved in 300μL of a 0.1% TFA solution in water,
loaded onto a conditioned column (the column was conditioned by washing twice with
300μL of acetonitrile [ACN] and centrifuged at 5000 g for 2 min each followed by washing
twice with 0.1% TFA solution) and centrifuged at 3000 g for 2 min. The column was
washed once with 300μL of a 5% ACN, 0.1% triethylamine (TEA) and then placed into a
2 mL sample tube.
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Table 1. Elution solutions for Thermo Scientific TMT-labeling peptides
Triethylamine (0.1%)
Fraction No.
Acetonitrile (%)
Acetonitrile (μL)
(μL)
Wash
5.0
50
950
1
10.0
100
900
2
12.5
125
875
3
15.0
150
850
4
17.5
175
825
5
20.0
200
800
6
22.5
225
775
7
25.0
250
750
8
50.0
500
500

Next, to fractionate the peptides, 300 µL of elution buffer from table 1 was added to
the column and centrifuged again to collect the fraction. This step was repeated to elute
the gradient fractions using the elution solutions into 2.0mL sample tubes. The liquid
contents of each sample tube were evaporated to dryness using vacuum centrifugation
and re-suspended in 0.1% formic acid (FA). The samples were sent to UNMC proteomics
core for LC-MS analysis.

Statistical analysis
Unless otherwise stated all experiments were done as biological triplicates with
technical triplicates. Graphs and figures were generated using SigmaPlot 11.0. The
parameters reported are average ± standard deviation. Volcano plots were created by
using Graphpad Prism version 8.2.1 and heat maps were created by using GENE-E
version 3.0.215. For all analyses, significance was set at P < 0.05.
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CHAPTER 3: RESULTS
Analog 19 modifies p65 and IKKβ in vitro by covalent binding:
To identify the sites that Analog 19 binds to on p65 and IKKβ, we incubated purified
recombinant p65 or IKKβ with Analog 19 or DMSO. A 1 µg sample of p65 and IKKβ were
digested with trypsin/chymotrypsin and tandem mass spectrometry was performed (Figure
6A). About 92 and 90% coverage were observed for untreated p65 and IKKβ samples. On
the other hand, 88 and 85% coverage were observed with 1mM analog 19 treated samples
(Figure 6B). Analog 19 treated p65 sample showed only 2 p65 peptide spectra that were
modified with analog 19 whereas 24 analog 19 modified IKKβ peptide spectra were
identified in analog 19 treated IKKβ sample (Figure 6C).
Analog 19 covalently modified cysteine residue 105 (Cys105) present in DNA binding
domain in p65 (Figure 6D). On the other hand, analog 19 covalently modified several
cysteine residues of IKKβ protein (Figure 6E), these include 46, 299, 412 and 524.
Previous studies have shown cysteine 46 is important for IKKβ kinase activity and is a
potential site for irreversible modification.[113] The Cys299 is part of the kinase domain
as it spans from 16-307 a.a. and Cys412 is part of the scaffolding/dimerization domain
that spans from 410-666 residues.[114] Of the 23 analog 19 modified IKKβ peptide
spectra, 15 corresponds to Cys524 modification. Cys524 residue is present in the
scaffolding domain as well suggesting covalent binding of analog 19 to IKKβ could disrupt
IKK dimerization which is a mechanism of action that has not been reported (Figure 6E).
Representative MS2 spectra of analog 19 modified peptide (+215 MW) in p65 and IKKβ
is summarized in Figure 6F and 6G respectively. The locations of analog 19 modified Cys
residues in p65 and IKKβ is shown in Figure 6H. The modifications on Cys residues are
in the structured regions of the proteins.
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Figure 6. A) Purified recombinant RELA or IKKβ was incubated with 19 or DMSO and
tandem mass spectrometry was performed on both trypsin and chymotrypsin digests of
the protein to identify all RELA and IKKβ peptides. Database searches with variable
modification of cysteine residues that correspond to conjugation of 19 (+215 Da) were
performed to identify modified peptides. B) Graph of the total sequence coverage of RELA
and IKKβ accomplished by peptide mapping with mass spectrometry. C) Analysis of the
number of significant MS2 spectrum with a Peptide Prophet probability ≥ 95% mapping to
RELA and IKKβ with 19 modified sites. D and E) Illustration of the mapping and abundance
of 19 modified cysteine residues in RELA and IKKβ. F and G) Representative MS2
spectrum of a 19 modified peptide in RELA and IKKβ. H) Protein Data Bank (PDB)
structure of RELA (1KN) and IKKβ (4KIK) with 19 modified cysteine residues indicated in
red and the kinase domain of IKKβ colored cyan. (Figure generated by Dr. Nick Woods)
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Analog 19 covalently binds to p65 and IKKβ proteins in cellular system:
To determine if analog 19 binds to p65 and IKKβ in a cellular system, we performed
click chemistry to tag proteins bound to 19 with biotin in cell lysates . The premise for this
study is that analog 20 (alkyne tagged analog 19) will covalently bind to proteins with
surface exposed Cys residues through the Michael acceptor. Subjecting the 20-tagged
protein lysate to click conditions with an azido-biotin will allow analog 20-tagged proteins
to be biotinylated. The 20-tagged biotinylated proteins can now be pulled down using an
avidin column and characterized by either MS or WB studies.
Ovarian cancer cell line A2780 was subjected to 10µM of analog 20 for 1h. The lysates
were subjected to click chemistry and biotin-Analog 19 bound proteins were eluted with
regeneration buffer. The eluted lysates were subjected to western blot analyses and
probed for p65, IKKβ, IKKγ and IκBα proteins, all of whom are members of the IKK
complex and have surface exposed Cys residues. We found that analog 19 was indeed
covalently binding to p65 and IKKβ in cellular system but not to IKKγ and IκBα (Figure 7).
Interestingly, from available protein structures we found that there are surface exposed
cysteine residues present on IKKγ (one) and IκBα (four), indicating that structural
compatibility between inhibitor and protein is critical for binding.
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Figure 7. Identification of 19 modified NFκB pathway proteins in cells. Cancer cells
(A2780) were incubated with 10µM of analog 20 (19 with an alkyne tag) for 1h. The lysate
was subjected to click reagents and azido-biotin. Biotin-tagged-19-bound proteins were
subjected to mono-avidin column. Biotin-tagged proteins were captured, the column was
washed to removed untagged proteins and the biotin-tagged-19-bound proteins were
eluted with regeneration buffer (6M urea/PBS). The eluted lysates were subjected to
Western blot analyses and probed for proteins (IKKβ, p65, IκBα and IKKγ) in the IKK
complex.
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Synthesis and evaluation of Analog 19 dimers for anti-NFκB activity:
The Natarajan lab previously showed that analog 19 inhibits IKKβ mediated
phosphorylation of IκBα which results in the inhibition of TNFα induced NFκB activity. Here
we showed that analog 19 covalently binds to p65 and IKKβ proteins in vitro and in cells.
Since p65 and IKKβ are part of the IKK complex we hypothesized that dimers of analog
19 would covalently cross-link p65 and IKKβ to proteins in the IKK complex. This is
previously unexplored mechanism for the inhibition of p65 or IKKβ.
To test this hypothesis, we synthesized three dimers of Analog 19 with varying
carbon linker lengths namely n3 (3 carbon linker chain), n7 (7 carbon linker chain) and
n12 (twelve carbon linker chain) (Figure 8A). We previously showed that Analog 19 inhibits
the TNFα induced NFκB activity in a luciferase reporter assay. We evaluated dimers n3,
n7 and n12 for their inhibitory effects in the TNFα induced NFκB activity assay. The A549
luciferase reporter cells specifically responds to TNFα induced NFκB activity by
expressing firefly luciferase. These cells were subjected to n3, n7 and n12 and their ability
to inhibit TNFα induced NFκB activity was determined. We found that n3 and n7 inhibited
TNFα induced NFκB activity in a dose dependent manner while n12 did not (Figure 8B).
All three dimers have the same targeting moiety, the only difference is the linker lengths.
This demonstrates that the linker length plays an important role in the ability of the dimers
to inhibit TNFα induced NFκB activity.
To further elucidate the mechanism of action of dimer, we treated two sets of ovarian
cancer cells OVCAR5 with 10µM concentration of analog 19 and n7 for 2h. One of the two
sets was stimulated with 40ng/ml TNFα for an additional 10 min. The lysates from both
sets were fractionated into cytoplasmic and nuclear fractions and subjected to western
blot analyses (Figure 8C). We observed that in the cytoplasmic fraction, upon TNFα
stimulation IκBα levels goes down due to IKKβ mediated IκBα phosphorylation, which
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leads to βTrCP mediated ubiquitination followed by proteasomal degradation of IκBα
(compare lanes 1 and 4 in Figure 8C). The loss of IκBα results in increased nuclear
localization of p65 (compared lanes 7 and 11 in Figure 6C). Analog 19 treatment showed
increase in IκBα levels as compared to vehicle treatment in the cytoplasmic fraction
(compare lanes 4 and 5 in Figure 8C) which correlates with a corresponding decrease in
nuclear p65 in the TNFα stimulated cells (compare lanes 10 and 11 in Figure 8C). A similar
comparison of IκBα and p65 levels in n7 treated cells stimulated with TNFα reveals a
complete blockade of IκBα degradation (compare lanes 4 and 6 in Figure 8C) and
dramatically reduced nuclear p65 levels (compare lanes 8 and 10 in Figure 8C)
comparable to the control. These studies clearly show that at equimolar concentrations
n7 is >6-fold and ~3-fold more potent (as determined by ImageJ quantification of the WB)
than analog 19 at inhibiting TNFα induced IκBα degradation and nuclear translocation of
p65, respectively.
Next, to evaluate the role of the linker length of the dimers in TNFα induced IκBα
phosphorylation and degradation along with nuclear translocation of p65, we treated
ovarian cancer cells OVCAR5 with 10 µM concentration of n3, n7 and n12 for 2h and
subjected one set to 40ng/ml TNFα for 10min. We collected the cytoplasmic and nuclear
fractions of the various treatments and subjected them to western blot analyses. We
observed that n3 and n7 potently inhibited IκBα phosphorylation in the presence and
absence of TNFα stimulation, while n12 did not. This was consistent with the reduced IκBα
degradation in the n3 and n7 treated TNFα stimulated cytoplasmic fraction, no such
reduction was observed in the n12 treated TNFα simulated cytoplasmic fraction. Since
inhibition of IκBα phosphorylation results in its binding to p65, we observed reduced p65
levels in the nuclear fraction that was treated with n3 or n7 and stimulated with TNFα
when compared to the corresponding control. Not surprisingly, we observed no such
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difference in p65 levels in the n12 treated TNFα stimulated nuclear fraction (Figure 8D).
Importantly, the results from the fractionation study are consistent with the results
observed in the luciferase reporter assay (Figure 8B). These observations clearly
demonstrate that linker length plays an important role in the dimers’ NFκB inhibitory
activity.

57

Figure 8. Synthesis and evaluation of analog 19 dimers A) Synthetic route to access 3(n3), 7- (n7) and 12- (n12) carbon linked dimers of analog 19. B) Evaluation of the n3, n7
and n12 in a TNFα-induced-NFκB luciferase reporter assay. (n=3, ±SD). C) Cancer cells
(OVCAR5) were treated with 10µM of analog 19 or n7 for 2h and stimulated with and
without 40ng/ml TNFα for 10 min post inhibitor treatment. The cytoplasmic and nuclear
fractions were isolated, and lysates were subjected to western blotting. D) Cancer cells
(OVCAR5) were treated with 10µM dimers n3, n7 or n12 for 2h and stimulated with and
without 40ng/ml TNFα for 10 min post inhibitor treatment. The cytoplasmic and nuclear
fractions were isolated, and lysates were subjected to western blotting.

58
Effect of dimer on TNFα induced global transcription:
Our studies thus far clearly demonstrate that analog 19 based dimers n3 and n7 inhibit
TNFα induced NFκB activation. Next, we wanted to determine the global effects of such
treatments using RNA-seq studies. We treated OVCAR5 cells with 10µM of n7 for 2h and
stimulated them with 20ng/ml of TNFα for 30 min and harvested cells using Trizol. We
isolated RNA from these samples and conducted RNA-seq analysis (UNMC sequencing
core). The volcano plot depicting differential RNA expression between TNFα stimulated
cells in the presence and absence of n7 treatment is summarized in Figure 7A. We
observed >2-fold expression change in ~132 genes with a false discovery rate (FDR) of
0.05 (Figure 9A). As expected, gene set enrichment analysis (GSEA) for Hallmark TNFα
signaling via NFκB genes with the TNFα stimulated samples yielded a normalized
enrichment score (NES) of +2.89. On the other hand, pretreatment with the dimer n7
yielded a NES of -2.30 (Figure 9B), indicating global inhibition of TNFα induced NFκB
gene expression by n7. Euclidean cluster analysis based heat map (2 fold change) for
Hallmark TNFα signaling via NFκB genes is summarized in Figure 9C. This clearly
demonstrates that the dimer n7 inhibits TNFα induced NFκB mediated transcription.
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Figure 9. A) Volcano Plot of differential RNA expression between the TNFα stimulated
cells and n7 treated TNFα stimulated cells. Significance set at p value ≤0.05 and fold
change +/- 2-fold. B) Gene Set Enrichment Analysis (GSEA) against the data set model
Hallmark TNFα signaling via NFκB for testing expression difference when comparing
changes for TNFα stimulated cells from control cells and for n7 treated TNFα stimulated
cells from control cells. Significance set at FDR ≤0.05. C) Euclidean cluster analysis based
heat map (2 fold change) of RNA seq Hallmark TNFα signaling via NFκB genes.
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Dimers form higher molecular weight covalent complexes with p65 and IKKβ
From the mass spectrometry and click chemistry experiments we found that Analog
19 covalently binds to p65 and IKKβ. We showed that dimers n3 and n7 inhibited NFκB
activity by inhibiting IκBα phosphorylation that resulted in reduced nuclear translocation of
p65. Next, we wanted to determine if the dimers cross-link p65 and IKKβ to inactivate their
function. To test this, we set up an in vitro reaction with recombinant p65 and IKKβ. We
took equimolar concentrations of recombinant p65 and/or IKKβ proteins and incubated
them with equimolar concentrations of dimers n3 or n7, analog 19 and a control compound
40-242 (dimer of iodoacetamide) for 24 h. Iodoacetamide is commonly used in mass
spectrometry to alkylate Cys residues. Di-iodoacetamide analog 40-242 was designed
such that the distance between the active methylene groups in 40-242 is ~16Å which is
similar to the distance between the Michael acceptors in the n7 dimer. A comparison of
n7 with 40-242 will determine the role of the spiro-isatin core in cross-linking NFκB
proteins.
The above reaction samples following incubation were subjected to western blot
analyses using anti-His antibody to detect his-tagged recombinant IKKβ and anti-p65
antibody. We found that there were additional high molecular weight bands present in the
dimer (n3 and n7) treated lanes as compared to p65 and IKKβ alone lanes. Also, we
observed reduction of p65 and IKKβ basal levels in the dimer treated lanes, whereas no
such reduction was observed in the p65 and IKKβ alone lanes. Moreover, in analog 19
and 40-242 treated lanes the banding profile was similar to the p65 and IKKβ alone lanes
(Figure 10A). We also subjected the gel to silver staining and found similar results i.e.,
high molecular weight bands were only observed in the dimer (n3 and n7) treated lanes
(Figure 10B). These results clearly demonstrate that dimers n3 and n7 indeed covalently
cross-link p65 and IKKβ, whereas the monomer analog 19 and the control compound 40-
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242 did not. This also demonstrates that dimerization of analog 19 is indeed responsible
for cross-linking p65 and IKKβ proteins and the spiro-isatin core is critical for recognition
and binding to p65 and IKKβ.
Next, to determine if the dimers can cross-link p65 and IKKβ in the cellular system, we
performed a series of experiments in various cell lines. We treated HEK 293, HPNE,
FTE282CII, MiaPaCa2, MiaPaCa2 IKKβ knockout, OVCAR5 and OVCAR5 p65 knockout
(KO) cells with and without dimer n3 for 2h at 10 µM concentration. The lysates from the
treatments were subjected to WB analyses and probed for p65 and IKKβ. We also looked
for Hsp90 protein since it is a chaperone protein for IKKβ and is required for stabilization
of the newly synthesized IKKβ.[12] We observed presence of high molecular weight bands
(HMW) for all three proteins in the cell lines tested with n3 dimer (Figure 10C).
In the Hsp90 immunoblot we observed one HMW band present at ~230 kDa in all the
cell lines treated with n3 showing no selectivity whatsoever for the non-transformed cells
vs the cancer cells and the knock-out lines. In nearly every cell line we also saw a slight
reduction on HSP90 levels in the treated samples.
In the p65 immunoblot, we observed three HMW bands at ~ 230, 140 and 100 kDa.
We also observed reduced p65 baseline protein levels in the n3 treated samples.
Importantly, the three HMW bands were not present in the OVCAR5 p65 knockout line
indicating that p65 is indeed involved in forming covalent bonds with the dimer and is
forming homo- or hetero-crosslinks with proteins in the IKK complex.
In the IKKβ immunoblot, we observed HMW bands only in the non-transformed cell
lysates at ~140 kDa and not in the cancer cell lines (MiaPaCa2 and OVCAR5) treated with
n3. Similar to findings with HSP90 and p65 immunoblots the baseline protein levels of
IKKβ was reduced in the n3 treated lysates. This reduction of IKKβ levels in the n3 lysate
was more robust in the cancer cell lines as compared to non-transformed cells. An
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exception for the above statement was in the OVCAR5 p65 KO cells where we observed
presence of HMW bands in the n3 treated lysate and baseline levels of IKKβ in the n3
treated lysate was more than those in the OVCAR5 cells. These observations suggest
that the dimer n3 indeed cross links p65 and IKKβ to proteins in the IKK complex. The
presence of p65 in the cancer cell lines leads to a more efficient degradation of IKKβ by
n3.
Next, we wanted to determine if (a) dimerization and (b) the spiro-isatin core of the
dimer n7 is required to cross-link proteins to p65 resulting in HMW bands. To test this, we
treated ovarian cancer cells OVCAR5 and A2780 with n7, analog 19 and 40-242. The p65
immunoblot revealed that n7 treatment leads to formation of HMW bands at ~100, 140
and 230 kDa at molecular weights identical to the ones obtained by n3 treatment. We also
tested analog 19 and 40-242 in these cells to determine the role of dimerization and the
spiro-isatin core in the formation of these HMW bands and found that both the treatments
did not form crosslinks as indicated by the absence of HMW bands in these treatment
lanes. We also looked at IKKβ protein profile and did not find any HMW bands or reduced
IKKβ levels which is in contrast to the n3 treatment (Figure 10D).
Next, we performed dose response studies to determine if the high molecular weight
(HMW) formation was a concentration dependent phenomenon. We treated ovarian
cancer cells OVCAR5 and pancreatic cancer cells S2013 with increasing concentrations
of n7 for 2 h. As expected, we observed a dose-dependent increase in the HMW bands
for both p65 and Hsp90 in both cell lines. Additionally, we did not see HMW bands when
probed for IKKβ and IKKγ (Figure 11A-B). Although at the highest concentration we did
observe degradation of IKKβ. These findings led us to conclude that the dimers are indeed
covalently cross-linking p65 to its binding partners. It is important to note that dimerization
and the spiro-isatin core are playing a critical role in recognition and binding.
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Figure 10. A) WB analysis of the in vitro p65 and IKKβ reaction with n3, n7, analog 19
and 40-242. Equimolar concentrations (7.72 µM) of the reactants were mixed and
incubated for 24 h at 4 °C and subjected to WB. B) Silver staining of the in vitro p65 and
IKKβ reaction with n3, n7, analog 19 and 40-242. C) WB analysis of panel of cell lines
treated with and without 10 µM concentration of dimer n3 for 2 h. Red arrows indicate
the HMW protein cross-link bands D) WB analysis of ovarian cancer cells A2780 and
OVCAR5 treated with 10 µM concentration of analog 19, dimer n7 or 40-242 for 2 h.
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Dimer binds to same sites and proteins as analog 19
In order to determine if dimers bind to same sites as analog 19 and further validate
that the HMW bands are indeed a result of dimerization of analog 19, we conducted a
competition assay. We treated ovarian cancer cells with increasing concentration of
analog 19 in combination with 10 µM concentration of n7 for 2h. Western blot analysis of
the lysates show a dose dependent decrease in the levels of HMW bands suggesting that
analog 19 and the dimer n7 bind to the same sites and proteins. Also, supporting previous
observations that HMW bands are a direct consequence of the dimerization of analog 19
(Figure 11C).

65

Figure 11. A) WB analysis of dose response study with n7 dimer, 2h treatment in ovarian
cancer cell line OVCAR5. B) WB analysis of dose response study with n7 dimer, 2h
treatment in pancreatic cancer cell line S2013. C) Competition study in ovarian cancer cell
line A2780 to demonstrate analog 19 binds to same sites as n7.
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Analog 19 binds to proteins involved in processing proteins in endoplasmic
reticulum
From the studies conducted thus far we established that the dimers are indeed
covalently cross-linking p65 with other proteins and are inhibiting the NFκB pathway
through a yet to be defined mechanism. Next, we wanted to determine the proteome wide
profile of the dimers. Since the monomer and the dimers binds to the same sites, to
determine the proteome wide profile we conducted mass spectrometry analyses of the
biotin-tagged analog 19-bound proteins from the OVCAR5 cell lysates. We treated
OVCAR5 cells with analog 20 (10µM) for 1 h, collected the lysates and subjected 2mg of
lysates to click reagents and TAMRA-biotin-azide. Biotin-analog 19 bound proteins were
then subjected to streptavidin column and biotin-tagged proteins were captured. The
column was washed to removed untagged proteins and the biotin-analog 19 bound
proteins were eluted with regeneration buffer and the eluent was subjected to mass
spectrometry analysis. We repeated this experiment twice. In the first run MS identified
198 proteins with atleast 2 unique peptides or more and in the second run MS identified
524 proteins with atleast 2 unique peptides or more. There were 76 proteins that were
common in the replicates, suggesting that these are high confidence analog 19 targets
(Figure 12A). To determine functional enrichments, we subjected the high confidence
protein set to string-db.org. We found that these proteins were involved in several critical
cellular functions and protein processing in endoplasmic reticulum (KEGG pathway) was
at the top of the list (Figure 12B). We also found that protein folding topped the list of
biological processes with this high confidence protein set. This suggested that analog 19
is binding to proteins that are involved in protein processing and folding in the ER.
Next, we wanted to determine if crosslinking of proteins by n7 resulted in reduced
stability. To test this, we treated OVCAR5 cells with dimer n7 for 2 h, 6 h ad 12 h at 10 µM
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concentration, isolated the lysates and performed TMT labelling of the peptides followed
by mass spectrometry. We processed and analyzed the proteomics data set derived from
the mass spectrometry analysis and created a heat map (+/-2-fold change) for the 76
proteins identified from the click-MS study by using GENE-E version 3.0.215. We found
that the protein abundance of few proteins changed with increase in time when treated
with n7 dimer (Figure 12C). Proteins cystatin-B (CSTB) which is a reversible inhibitor of
cysteine proteinases cathepsin B and proteins vimentin (VIM) and lamin-B1 (LMNB1)
showed increase in abundance. We observed a decrease in abundance among others
such as heat shock protein beta-1 (HSPB1) which plays a role in stress resistance by
maintaining protein confirmation and in activated RNA polymerase II transcriptional
coactivator p15 (SUB1) which plays a role in the transcription.
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Figure 12. Identification of direct targets of 19 in cells. A. Cancer cells (OVCAR5) were
incubated with 10µM of analog 20 for 1h. The lysates were subjected to click reagents and
TAMRA-biotin-azide. Biotynlated 19-tagged proteins were isolated on a streptavidin
column subjected to MS analyses. B. The 76 proteins identified through click-MS were
subjected to string-db.org and the top hits of the KEGG pathway are displayed. C) Heat
map depicting the abundance of proteins identified through click-MS in n7 treated samples
for 2h, 6h and 12h, +/-2 fold change
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Dimer induces UPR pathway:
Analog 19 covalently binds to at least 76 proteins with high confidence and KEGG
pathway analyses shows that they are involved in protein processing and folding. Since
the analog 19 and n7 appear to bind to the same proteins we hypothesized that n7
treatment could induce ER stress. To test this hypothesis, we treated OVCAR5 cells with
10µM concentration of n7 for 2h, 6h and 12h, and harvested cells using Trizol. We isolated
the RNA from the samples and conducted RNA sequencing and analysis (UNMC
sequencing and epigenetics core). The volcano plot for differential RNA expression
between the control cells and n7 treated cells for 2h treatment identified 113 genes > 2fold expression with FDR < 0.05 (Figure 13A). Gene set enrichment analysis (GSEA) for
unfolded protein response pathway genes were positively enriched for in the n7 treated
samples. The normalized enrichment score (NES) were +1.22 for 2 h and +1.41 for 6 h
n7 treatment (Figure 13B). Euclidean cluster analysis (2-fold change) for Hallmark
Unfolded protein response genes showed a time dependent increase in the expression
for majority of genes in the hallmark UPR gene set (Figure 13C). Together these data
suggest that the dimer n7 is a UPR activator.
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Figure 13. A) Volcano Plot of differential RNA expression between the control cells and
n7, 10 µM, 2 h treated cells. Significance set at p value ≤0.05 and fold change +/- 2-fold.
B) Gene Set Enrichment Analysis (GSEA) against the data set model Hallmark Unfolded
Protein Response for testing expression difference when comparing changes for n7
treated cells for 2h and 6h from control cells. Significance set at FDR ≤0.05. C) Euclidean
cluster analysis based heat map (2 fold change) of RNA seq Hallmark Hallmark Unfolded
Protein Response genes.
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Dimer n7 induces UPR and apoptosis in the cancer cells
The UPR pathway is regulated by three major transducers: ATF6, PERK and IRE1α.
Upon UPR induction inactive ATF6 is cleaved to its active form in the golgi apparatus and
mediates the transcription of ER chaperones in the nucleus. PERK phosphorylates eIF2α
leading to inhibition of translational initiation resulting in reduced protein folding load on
the ER. IRE1α splices out a small intron from the XBP1 mRNA resulting in production of
active XBP1 transcription factor that mediates the transcription of ER chaperones. PERK
and IRE1a are considered major responders to ER stress and ATF6 is used to fine tune
the response.
Since we observed enhanced transcription of UPR genes, we next looked at ER stress
response protein levels in ovarian cancer cell line OVCAR5. We also observed that dimer
covalently cross-links proteins in non-transformed as well as ovarian cancer cells,
therefore we included non-transformed immortalized in the above study. We compared
the efficacy of the dimer with the parent compound analog 19 in their ability to induce UPR.
Briefly, FT282-C11 and OVCAR5 cells were treated with n7 or analog 19 (10µM) for 2 h
and the lysates subjected to Western blot analyses with ER stress related antibodies
(Figure 14A). We found that XBP-1 spliced protein levels went up in n7 treated lysates
derived from non-transformed immortalized cells, whereas the levels did not change in the
OVCAR5 cancer cells when compared to control cells. We also observed an increase in
the XBP-1 unspliced protein with the dimer treatment in the FT282-C11 cells. This
indicates the activation of the IRE1 pathway activation of the UPR arm by n7 in the
immortalized FT282-C11 cells. We did not see any such activation with analog 19. The
ATF6 levels significantly decreased in both the cell lines, indicating the activation of this
arm of the UPR pathway in both the cell lines is identical. The levels of ATF6 were not
affected in both cell lines at equimolar concentration of analog 19. We observed a slight
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increase in the p-eIF2α levels with dimer n7 treatment in the immortalized FT282-C11
cells while there was considerably larger increase in p-eIF2α levels in n7 treated OVCAR5
cells, indicating more pronounced activation of PERK pathway in cancer cells over nontransformed cells.
If the UPR fails to restore proteostasis, the cells activate the apoptotic program.
Probing the above membranes for apoptotic proteins revealed a robust increase in
cleaved-PARP and cleaved-caspase 7 levels in the OVCAR5 cells treated with the dimer
n7. A similar increase was observed in cleaved PARP but not cleaved-caspase 7 in
FT282-C11 cells treated with n7. Analog 19 treatment induced slight increase in cleavedPARP levels in in FT282-C11 and OVCAR5 cells. Analog 19 induced cleaved-caspase 7
in OVCAR5 cells but not in FT282-C11 cells.
It is known that ATF6 and IRE1 arms of UPR are mostly involved in cell survival and
failure to restore proteostasis results in the activation of CHOP by PERK arm of the UPR.
Selective transcription of ATF4 upon phosphorylation of eIF2α promotes transcription of
ER stress target gene CHOP under unmitigated stress conditions to trigger the apoptotic
program. Based on these and our results with the dimer n7 and analog 19 in OVCAR 5
and FT282-C11 cells we can come to the following conclusions. The dimer is inducing the
robust activation of the cell survival arms of UPR in the FT282-C11 cells as indicated by
the XBP1 splicing and reduced ATF6 levels and at these concentrations and time points
the cells have yet to activate the UPR mediated apoptotic program indicated by the
absence of cleaved caspase 7. Whereas in the OVCAR5 cells, the IRE1 arm is already
functioning at maximal capacity and the stress induced by the dimer results in the
activation of PERK mediated activation of the apoptotic program. For the most part the
monomer analog 19 has little effect on the UPR pathways indicating that the dimerization
is responsible for the induction of UPR mediated cell death.
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A time course study in the OVCAR5 cells with the dimer n7 was conducted to
determine the time-dependent effects on the UPR genes. Briefly, OVCAR5 cells were
treated with dimer n7 for 2, 6, and 12 hours at 10 µM concentration and lysates were
subjected to western blot analyses. We found a time dependent increase in the levels of
BiP and CHOP. We observed a sustained upshift in the molecular weight of PERK levels
is indicative of phosphorylation mediated activation of PERK. This was consistent with a
time dependent increase in the p-eIF2α (PERK substrate) levels while the total eIF2α
levels remained constant. We observed no significant change in IRE1 levels whereas
there was a time-dependent decrease in ATF6 levels. Together, these results indicate that
in resting OVCAR5 cells IRE1 pathway is already activated to handle the higher protein
folding load. The dimer n7 activates ATF6 and PERK arms of the UPR in OVCAR5 cells.
Moreover, at the indicated concentration n7 induces irremediable ER stress to activate
PERK mediated apoptotic program in OVCAR5 cells (Figure 14B). We also tested a panel
of ovarian cancer cell lines (CaOV3, OVCAR8 and KURAMOCHI,) for n7’s (1 µM) ability
to induce apoptosis using caspase 3/7 activity assay as a read out following a 6h treatment
and found that n7 induced caspase 3/7 activation. (Figure 14C).
These results led to the conclusion that the dimerization of analog 19 result in PERK
mediated activation of the caspase 7 dependent apoptotic program in cancer cells.
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Figure 14. A) WB analysis of FT282 CII and OVCAR5 cells treated with 10 µM
concentration of analog 19 or n7 for 2 h. B) WB analysis of time course study with n7
dimer, 10 µM concentration in ovarian cancer cell line OVCAR5. C) Caspase 3/7 activity
assay for n7 (1 µM, 6 h) treated ovarian cancer panel.
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Dimer inhibited growth of cancer cell lines with greater potency as compared to
parent compound analog 19
We next tested the growth inhibitory effects of the dimer in the ovarian cancer cells to
determine if the dimers are more potent in inhibiting the growth of the cancer cells over
the parent compound analog 19. We treated a panel of ovarian cancer cells with
increasing concentrations of analog 19, n12 and n7 and incubated them for 72 h. We used
presto blue to determine the growth inhibitory potential of the compounds. We found that
dimers were more potent in inhibiting the cell growth across all cell lines when compared
to analog 19. Analog 19 had an EC 50 in the range of ~ 2-8 µM against seven ovarian
cancer cell lines, whereas dimer n7 showed EC 50 in the range of ~ 0.3-1.5 µM which is
approximately 2 to 14-fold more potent across the panel. Dimer n12 (EC 50 in the range of
~ 0.4-4 µM) was ~1.5 to 10-fold more potent than analog 19 across the panel (Figure 15A).
This further corroborated with our previous finding that the linker length plays a role in
efficacy of the dimer. Analog 19 and dimer n3 were subjected to the NCI 60 cell line panel
and found that n3 was more potent than analog 19 (Figure 15B).
Finally, we wanted to test the role of the Michael acceptor in the potency of the dimer.
Dr. Rana synthesized 36-297 dimer which is reduced form of dimer n7 to address the
above question. We found that n7 was ~10-fold (EC 50 = 0.2 µM) more potent than analog
19 (EC 50 = 2.3 µM), whereas the reduced dimer 36-297 (EC 50 = 18.5 µM) was ~100-fold
less potent than n7, indicating the importance of the Michael acceptor for the activity of
the dimer (Figure 15C). To determine the functional role, dimers n7 and 36-297, we
subjected them to the TNFα induced NFκB activity luciferase reporter assay. This showed
that n7 inhibited the TNFα induced NFκB activity in a dose dependent manner whereas
36-297 did not inhibit this activity (Figure 15D).
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Figure 15. A) Table depicting the EC 50 of analog 19, n7 and n12 in a panel of ovarian
cancer cells. (n=3, ±SD). B) NCI-60 cell line screen for analog 19 and n3. C) Growth
inhibitory effect of n7 and its reduced form 36-297 on A2780 cells. (n=3, ±SD). D)
Evaluation of the n7 and 36-297 in a TNFα-induced-NFκB luciferase reporter assay. (n=3,
±SD).
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CHAPTER 4: DISCUSSION
Our lab previously reported the development of analog 19, an isatin derived spirocyclic
analog with α-methylene-γ-butyrolactone functionality, that covalently binds the IKKβ and
p65 resulting in the inhibition of TNFα-induced IKKβ-mediated NFκB activation. Analog 19
inhibited cancer cell growth, induced apoptosis, inhibited tumor growth in an orthotopic
ovarian cancer model and synergized with cisplatin.[64]
Work done with parthenolide, a naturally occurring sesquiterpene lactone containing
the α-methylene-γ-lactone moiety, showed that parthenolide inhibits the NFκB activation
by covalently binding to the Cys179 residue of the IKKβ and Cys38 residue of the p65.[57,
58, 115] Similarly, helenalin binding to Cys38 of p65 interfere with the DNA binding ability
of p65 thus inhibiting the NFκB activity.[56] Along these lines we wanted to identify the
Cys residues on IKKβ and p65 targeted by analog 19. We did enzymatic digestion of
recombinant IKKβ and p65 incubated with and without analog 19 followed by tandem MS
analysis and identified the covalently modified cysteine residues on IKKβ and p65.
We found that analog 19 binds to Cys105 which is present in the DNA binding domain
in p65 suggesting a possible role in inhibiting p65-DNA binding. The N-terminal DNA
binding domain (DBD) of p65 is also called Rel homology region (RHR) which spans ~300
residues and is involved in important functions including dimerization, nuclear localization
and DNA binding.[116, 117] Previously, Cys38 and Cy120 have been targeted for
inhibiting the DNA binding ability of p65, this is the first time an inhibitor is known to target
the Cys105 residue of p65.[58] Analog 19 also modified several cysteine residues of IKKβ
protein including Cys46 and Cys299 present in the kinase domain and Cys 412, Cys524
present in the scaffolding domain. Cys46 has been found to exert an important role in
IKKβ kinase activity and its mutation was shown to cause resistance against
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dihydromyricetin (DMY) that suppresses inflammation by binding to Cys46 of IKKβ.[113]
In another study, electrophilic quinone methide (QM) Michael acceptor covalently modified
multiple cysteine residues in the IKKβ kinase region (KD) including the Cys46 and Cys299
to inhibit the NFκB activity.[118] The scaffolding/dimerization domain (SDD) spanning from
410-666 residues is not only essential for IKKβ dimerization but also for kinase activity as
the KD interacts with the SDD for its activity.[114] This suggests a role of analog 19 in
inhibiting the kinase activity and the IKK complex formation.
From the click chemistry study followed by biotin pull down and WB, we found that
analog 19 covalently binds to p65 and IKKβ in the cellular system whereas, other critical
IKK signalosome proteins IKKγ and IκBα did not show any such binding despite the
presence of surface exposed cysteine on them. This indicates the critical role of
location/context of the surface exposed Cys residues and the structural compatibility
between inhibitor and protein. This chemoproteomic strategy is being widely used now to
identify all possible protein targets of covalent inhibitors.[119] Similar studies have been
done previously that used click chemistry and alkynyl inhibitor probe that identified
covalent binding of an anti- NFκB agent dimethyl fumarate (DMF) with recombinant p65
protein and p65 in breast cancer cell lysates.[120]
From work done in a previous study we know that analog 19 exhibits anticancer activity
in vitro and in vivo by inhibiting the NFκB activity by covalently binding to p65 and IKKβ.[64]
Thus, the incorporation of two Michael acceptors in one compound (dimers of analog 19)
could target surface exposed cysteine residues on p65 and IKKβ resulting in covalent
cross linking of these proteins. Previously carbamate and carbonate dimers of
sesquiterpene melampomagnolide-B (MMB) have been synthesized to provide multiple
covalent interaction sites on the glutathione-cysteine ligase enzyme to inhibit the
glutathione pathway. From this study it was found that the dimers of melampomagnolide
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B exhibited potent anticancer activity against hematological and solid tumor cell lines.[121]
Thus, to test this idea, we synthesized dimers of analog 19 with varying carbon linker
lengths namely n3 with 3 carbon linker chain length, n7 with 7 carbon linker chain length
and n12 with twelve carbon linker chain and evaluated their potency against inhibiting the
TNFα induced NFκB activity. We found that n3 and n7 inhibited TNFα induced NFκB
activity in a dose dependent manner while n12 did not. This indicated that dimers indeed
function as NFκB inhibitors and the linker length plays a role in their NFκB inhibitory
activity.
Transcription factor p65 is present in the cytoplasm in an inactive state in complex with
IκBα. Upon activation by extracellular signals like TNFα, IL-1, etc, IκBα is phosphorylated
by IKKβ, ubiquitinated and degraded by proteasomes, releasing p65. Since p65 has
nuclear localizing signal region, it translocates to the nucleus, binds to κB elements on
DNA and activates gene expression.[20, 122] The nuclear localization of p65 requires
IκBα to be phosphorylated, ubiquitinated and degraded. Various types of inhibitors have
been shown to inhibit p65 nuclear translocation by targeting the various steps of the
pathway. IKKβ kinase inhibitors block the phosphorylation of IκBα are one such example.
Compounds like parthenolide and arsenite inhibit the IKKβ kinase activity by interacting
with Cys179, thus inhibiting the downstream p65 nuclear localization in response to
upstream signals like TNFα and LPS.[57, 123, 124] A fungal epoxyquinoid,
Dehydroxymethylepoxyquinomicin (DHMEQ) which is found to have anti-inflammatory
and anti-tumor activity in multiple mouse models has been reported to directly inhibit the
p65 nuclear translocation and thus inhibited the constitutively activated NFκB activity.[125]
We tested our dimers to see their effect on p65 nuclear localization and observed that at
10 µM concentration treated for 2 hrs and compared the effects with the monomer 19.
Analog 19 partially inhibited the TNFα induced NFκB activity in TNFα stimulated cells as

80
observed by partial inhibition of p65 nuclear localization. Whereas, dimer n7 inhibited the
TNFα induced NFκB activity in TNFα stimulated cells with greater potency as observed by
robust inhibition of IκBα degradation and p65 nuclear localization. When we compared the
dimers n3, n7 and n12 in the above assay we observed that longer linker lengths resulted
in reduced inhibition of NFκB pathway. We saw complete inhibition of phosphorylation and
subsequent degradation of IκBα and nuclear localization of p65 by dimer n3 treatment in
TNFα stimulated cells. Whereas n7 partially inhibited the pathway and n12 did not show
any inhibition of the pathway. From this study we can conclude that the dimers are
inhibiting the p65 nuclear localization by inhibiting the phosphorylation degradation of IκBα
and that this inhibition is dependent on the linker lengths of the dimer.
NFκB pathway regulates expression of numerous genes involved in the apoptosis,
cellular proliferation, immune and inflammatory responses. TNFα stimulation activates the
NFκB pathway leading to induction of p65 driven gene expression. Consistent with this
observation we found that gene expression for hallmark TNFα induced NFκB pathway was
positively enriched in OVCAR5 cells stimulated with TNFα. Pretreatment with the dimer
n7 treatment followed by TNFα stimulation resulted in a negative enrichment hallmark
TNFα induced NFκB pathway geneset. Euclidean cluster analysis based heat map (2 fold
change) for Hallmark TNFα signaling via NFκB genes showed an increase in the
expression for majority of genes in the TNFα stimulated cells and a robust decrease in the
expression for majority of genes in the dimer n7 pretreated cells. This study demonstrates
potent inhibition of TNFα induced NFκB pathway activation by the dimer n7.
The presence of Michael acceptors at the ends of dimers n3 and n7 suggests that
they should cross link p65 and IKKβ resulting in higher molecular weight covalently crosslinked homo- or hetero-mers of p65 and IKKβ. An in vitro reaction with recombinant
proteins and the dimers probed by Western blot and silver staining indeed showed HMW
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bands. Not surprisingly no such HMW bands were observed with analog 19 treated
samples. This indicated that the cross linking of proteins was indeed a consequence of
dimerization of analog 19.
To assess the requirement of isatin-derived spirocyclic core for such dimerization we
synthesized 40-242 an iodoacetamide dimer which has similar distance between its active
methylene groups as the distance between the Michael acceptors in the n7 dimer.
Treatment of 40-242 with recombinant p65 and IKKβ under identical conditions as n7
treatment showed no HMW bands highlighting the importance of the spirocyclic core in
n7.
We also tested the dimers against a panel of cell lines from various tissue type
including non-transformed immortalized human embryonic kidney cells HEK 293,
pancreatic cells HPNE and fallopian tube epithelial cells FTE282CII as well as pancreatic
cancer cells MiaPaCa2 and ovarian cancer cells OVCAR5 to assess the ability of dimers
to cross-link proteins. From the WB studies we found that the dimer n3 treatment resulted
in HMW proteins with Hsp90 and p65 in all the cell lines, whereas IKKβ HMW protein
cross links were only present in the non-transformed cell samples and not in the cancer
cells. We also observed that IKKβ baseline levels were also reduced more robustly in the
cancer cells as compared to non-transformed cells with the dimer treatment. These result
indicate that the dimer is forming crosslink with p65 and Hsp90 protein without showing
any preference for normal or cancer cells and that there is a higher rate of cross-linking of
the IKKβ protein and their subsequent clearance in the cancer cells as compared to the
normal cells.
We found that the HMW bands for p65 were absent in OVCAR5 p65 KO cells
indicating that p65 is indeed involved in forming covalent bond with the dimer and is
forming homo- or hetero-mer crosslinks. Whereas for IKKβ we observed presence of
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HMW bands and greater levels of baseline IKKβ levels in the n3 treated OVCAR5 p65 KO
samples, whereas the HMW proteins were absent in the parental cell line. This implicates
the involvement of the p65 in the degradation of IKKβ with the dimer n3 treatment in the
cancer cells, whereas the IKKβ knock out did not show any such effect.
Similar to n3 treatment, we found formation of HMW cross-link p65 protein bands in
ovarian cancer cells when treated with dimer n7 whereas no such bands were present in
analog 19 and 40-242 treated cells which was similar to our results from the recombinant
protein reaction. This further validated our finding that the dimerization of analog 19 and
the spiro-isatin core play a critical role in the recognition, binding and consequently crosslinking the proteins leading to formation of these HMW proteins. Also, from the dose
response studies in ovarian cancer and pancreatic cancer cell line we observed increase
in levels for p65 and Hsp90 HMW proteins with increasing n7 concentrations indicating
that protein cross-linking function of dimer is more robust at higher concentration. We also
looked at other IKK proteins and did not see HMW proteins with WB when probed for IKKβ
and IKKγ, but we did see decrease in IKKβ levels at higher n7 concentration suggesting
that like with n3 treatment there could be enhanced rate of clearance of IKKβ protein
crosslinks that is responsible for reduced IKKβ levels. We further confirmed that the dimer
binds to the same sites as analog 19 by performing a competition assay and that the p65
HMW protein bands observed were a direct consequence of dimerization.
These results demonstrate that dimerization of analog 19 potently inhibits NFκB
pathway through a novel mechanism of forming covalent cross links with the NFκB
pathway proteins. Since we are cross linking proteins and forming HMW aggregates, there
is bound to be formation of protein aggregates that are recognized as misfolded proteins
by the cellular protein surveillance/quality control machinery.
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We also determined the proteome wide selectivity of analog 19 by performing the click
chemistry followed by biotin pull down and MS analysis with analog 20. High confidence
proteins identified from the MS analyses were subjected to KEGG pathway analyses using
online string database. This identified protein processing in ER and protein folding
processes as biological processes associated with analog 19 bound proteins. We found
that some of the analog 19 target proteins showed an increase or decrease in abundance
when treated with dimer n7. Protein CSTB, a reversible inhibitor of cysteine proteinase
cathepsin B increased in abundance with dimer treatment. Cathepsin B is overexpressed
in multiple metastatic cancers including breast cancer, colorectal cancer, ovarian cancer
and melanoma.[126, 127] Another protein HSPB1, which maintains protein confirmation
by avoiding their aggregation and promoting clearance, play an important role in stress
resistance.[128] So not only was dimer potentially binding to proteins involved in protein
processing and folding processes, but it was modulating abundance of some of the
proteins further contributing to cellular stress. RNA-seq analyses with the dimer n7
revealed that unfolded protein response pathway genes are activated. GSEA of hallmark
unfolded protein response pathway geneset showed positive enrichment in n7 treated
samples and their NES scores increased over time. Euclidean cluster analysis based heat
map (2 fold change) for hallmark unfolded protein response pathway genes showed an
increase in the expression for UPR genes in n7 treatment indicating that n7 is an UPR
activator.
Endoplasmic reticulum plays an important role in the proper folding of proteins.
Dysfunction in this process leads to accumulation of unfolded proteins in the ER causing
ER stress. Three distinct pathways are activated to handle the stress and return it to
normal proteostasis. ER stress triggers a cytoprotective UPR, wherein protein translation
is inhibited through PERK activation, molecular chaperones such as BiP are rapidly

84
synthesized to enable increased folding and ERAD degradation mechanism is initiated to
remove misfolded proteins from the cell. The increased biomass needs in a tumor cell
forces them to coopt the UPR pathway. This results in elevated levels of UPR proteins in
cancer cells as compared to the normal cells. Under prolonged ER stress the adaptation
(cytoprotective role of UPR) threshold is breached and a cytotoxic program is activated
through the production of CHOP transcription proteins. CHOP regulates the transcription
of various apoptotic proteins and mediates cell death when the apoptotic threshold is
breached.[129] The dimer is cross linking proteins and potentially accumulating
aggregates of cross-linked proteins in the cell as indicated by the WB studies, thus
inducing UPR. Few inhibitors have been shown to work along the same principle like the
proteasome inhibitor bortezomib sensitizes various tumor types to chemotherapy such as
cisplatin and doxorubicin by increasing the levels of ubiquitinated protein.[130] Verteporfin
an inhibitor of the YAP (Yes-associated protein 1) induces apoptosis in colorectal cancer
cells by enhancing the oligomerized protein (particularly sequestrome p62 and STAT3
transcription factor) load [131].
Although the dimer covalently cross-linked proteins to form HMW proteins in both nontransformed and cancer cells, it induced activation of different arms of UPR. We observed
activation of IRE1 pathway arm of the UPR in n7 treated immortalized FT282 CII cells,
which did not change in OVCAR5 cells. In the cancer cell line OVCAR5, we observed
elevated p-eIF2α levels, indicating the activation of the PERK arm of the UPR by the n7
treatment while no such change was observed in the non-transformed FT282 CII cells.
The activation of ATF6 arm of the UPR pathway in both the cell lines was similar. This
suggests that n7 treatment in cancer cells resulted in breaching the adaptation threshold,
while in immortalized cells the activation of UPR was cytoprotective. Previous studies with
Tunicamycin and thapsigargin treatment have revealed that prolonged stress conditions
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show transient activation of the IRE1 arm of UPR whereas the PERK activation is
sustained, and that artificially sustaining the IRE1 activation results in enhanced cell
viability.[68] This suggests the important role that IRE1 plays in reducing the ER stress to
maintain cell viability.
In a previous study Carlberg and Larsson tested tunicamycin’s effect on the viability of
normal and SV40- transformed mouse fibroblast and found that it selectively killed the
transformed fibroblast via apoptosis by increasing the intracellular Ca2+.[132] Breaching
the adaptation threshold in cancer cells resulted in the activation of the apoptotic program.
This is consistent with our observation of robust increase in cleaved-PARP and cleavedcaspase 7 levels in the cancer cells treated with the dimer n7. No such increase is seen
in non-transformed immortalized cells, indicating the cytoprotective effect or that the cells
are still in the adaptation phase. IRE1 activation and robust XBP-1 splicing observed in
non-transformed immortalized cells possibly counteracts the ER stress load induced by
the dimer, thus the UPR mediated apoptosis is not induced. Whereas in the cancer cells,
we observed no increase in XBP1 splicing and the spliced XBP1 levels in the control was
comparable to that of n7 treated levels in FTE282 CII cells. This suggests that the IRE1
pathway is constitutively activated in cancer cells to handle the higher protein folding
needs. XBP-1 splicing is known to mitigate the ER stress in secretory B cells in multiple
myeloma and pancreatic adenocarcinoma cells as well as in triple negative breast cancer
cells to facilitate growth and survival. Since IRE1 pathway is already activated in the
cancer cells and possibly at its maximal activation state, dimer treatment results in
activation of the PERK/CHOP arm of the UPR to trigger the apoptosis program. On the
other hand, analog 19 did not induce the activation of any arm of the UPR, indicating that
the dimerization is responsible for the ER stress induced UPR activation.

86
Also, from the dimer treated time-course study with the cancer cells, we observed the
activation of ER chaperone BiP, PERK and the ATF6 proteins, as well as increase in peIF2α, CHOP and cleaved-PARP protein levels in a time-dependent manner with the
dimer n7 treatment. UPR activators like thapsigargin have been known to disrupt the Ca2+
homeostasis causing cell death by inducing sustained elevation of ATF4, CHOP, and BiP
levels at 0.1 uM concentration. This was followed by a gradual increase in cleaved PARP
levels. From this study it was found that the cell death was induced by sustained Ca2+
depletion and sustained UPR.[95]
To maintain proteostasis, a plethora of proteins assist in folding and quality control of
proteins in the ER. UPR comes into play in cases where the protein folding machinery is
overwhelmed and is unable to meet the protein folding demands. This process is
reversible where once the cells return to the resting proteostasis levels, the UPR is
resolved. Since cancer cells have higher biomass load, they are dependent on UPR for
driving their malignant transformation.[133] Thus, in multiple cancer types there is
upregulation of one or more arms of UPR providing a cytoprotective role in the cells. In
multiple cancers, there are reports of IRE1 pathway activation to cope with the protein
load.[134-137] This is similar to what we see in our study with FTE282 C11 cells where
under stress condition we see robust XBP1 splicing to cope with the misfolded protein
load and less of cell death. Additionally, we see high basal XBP1 splicing in the OVCAR5
cells which is equivalent to levels of XBP1s in normal cells under stress. Since, the IRE1
pathway is activated to a higher level in cancer cells, the adaption threshold limit is easily
breached under irremediable stress conditions as compared to in normal cells. This
provides a therapeutic window for the UPR activators (Figure 16).
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Figure 16. Model for developing UPR inducers for triggering irremediable stress in cancer
cells.
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Finally, growth inhibitory studies showed that the dimers were more potent in inhibiting
the growth of the cancer cells when compared to the parent compound analog 19. The
linker length did have an effect on the dimer growth inhibitory efficacy. The linker length
determines the distance between the two functional groups of the dimer. The inter-thiol
distance between the surface exposed cysteine residues of proteins in a complex are in
low Å range thus the lower linker length dimer has greater multi-covalent interaction
opportunities than the dimers with higher linker lengths, this could be the reason of n3
dimer showing more potency than n7 which in turn shows more potency than n12. Analog
19 and dimer n3 were also screened against the NCI 60 cell line panel and the results
showed that n3 was more potent than analog 19. The leukemia panel was the most
sensitive while the CNS panel was the least. We also showed that the Michael acceptor
is critical for the activity of the dimers.
Unlike thapsigargin and tunicamycin which target the SERCA pump and protein-Nglycosylation respectively to induce UPR, the dimers presented here crosslink proteins to
increase the levels of misfolded proteins. This results in UPR mediated apoptotic cell
death in cancer cells. UPR is also known to activate the NFκB by reducing the translation
of IκBα and activating the IKKβ through different mechanisms. This pathway is
simultaneously targeted by the dimers via multiple mechanism. That is, dimer binds to
IKKβ and inhibit the phosphorylation of IκBα. It also binds to p65 downstream of IKKβ and
inhibits its nuclear translocation and finally they induce degradation of IKKβ in a p65
dependent manner. Prolonged ER stress inhibits the NFκB pathway activation further by
inhibiting the TRAF2 activation and inhibiting the p65 DNA binding function. Thus, further
improved NFκB pathway inhibition in the dimer as compared to the monomer analog 19
could be attributed to the prolonged ER stress inhibition of the NFκB pathway.
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OVERALL CONCLUSION
My dissertation was aimed at characterization of a novel series of dimeric covalent
inhibitors that conjugated p65 and IKKβ to other proteins. The consequence of such
effects were inhibition of NFκB activity and induction of UPR. From this work we conclude
that the dimers were more potent than the monomer analog 19 in inhibiting the TNFαinduced IKKβ-mediated NF-κB activation. The length of the linker in the dimers play a
pivotal role in its efficacy with smaller linker length (n3) showing most efficacy and larger
linker length (n12) showing least efficacy. Dimers covalently bind to surface exposed
cysteine residues of p65 and IKKβ to form higher molecular weight protein complexes.
The binding and recognition of Cys residues by the dimer is due to the spiro-isatin core
and cross-linking of proteins is a consequence of dimerization. The dimer breaches the
adaptive signaling threshold of the UPR in cancer cells and activates the
PERK/eIF2α/CHOP arm leading to robust apoptotic cell death. The lower proteostasis in
normal cells keeps the immortalized non-transformed cells in the adaptation state by
robustly inducing IRE1 mediated XBP1 splicing. Dimers through a novel mechanism inhibit
the activation of the NF-κB pathway while simultaneously inducing irremediable ER stress
to trigger the cancer cell apoptotic program.
It is known that treating cancer through UPR modulation has great potential and
simultaneous NF-κB pathway inhibition provides added benefits in multiple cancers.
Overall, there have been number of small molecules optimized for targeting the UPR, here
we modified a known NF-κB pathway inhibitor to induce UPR mediated apoptosis, which
is novel and worthy of further exploration.
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FUTURE DIRECTION
We established from the cell line data that the dimer showed enhanced inhibitory
activity against TNFα-induced IKKβ-mediated NF-κB activation and induced UPR
mediated apoptosis in the cancer cells. We still need to explore the mechanism of UPR
induction in the cancer cells.
We would like to expand our studies to understand how our dimer act inside the cells,
as to what is the effect of the dimer on the folding and misfolding of proteins and verify its
contribution to the induction of UPR. This can be persued by first measuring the
unfolded/misfolded protein load in the cell with and without treatment with dimer. A thiol
probe tetraphenylethene maleimide (TPE-MI) has recently been used to measure the
unfolded protein load in the cell. TPE-MI is a fluorogenic dye which does not need
expression of any reporter protein. TPE-MI fluorescence enhances upon binding to free
cysteine thiols present on unfolded proteins which are otherwise buried in the folded
proteins.[138] It is important to use a probe that not only enters the cell membrane but
also shows signal only upon binding to its target. We can use TPE-MI and an ER tracker
to determine the unfolded protein load in the ER in the dimer treated cells.
As we have discussed extensively over this thesis, TNFα-induced IKKβ-mediated NFκB activation is very important signaling pathway for normal cell functioning and its
extremely dysregulated is multiple cancer as well as other diseases. Compared to
conventional NF-κB inhibitors, dimers provide advantages as therapeutic agent. First is
that it potently inhibits NF-κB pathway at multiple target sites and that short exposure time
is sufficient to induce UPR mediated cell death. Short term goal of our studies is to take
our studies to in vivo testing, where we use xenograft mice tumor models to test the effect
of our drug on reduction of tumor load, metastasis and inflammatory responses associated
with tumor induction. An ideal xenograft model would be by generating tumor induced by
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patient derived tumor cells, by intraperitoneal or intravenous injection of the human tumor.
Similar studies have been done for parthenolide in multiple tumor models, like renal cancer
model.[139] We have shown effect of our drug in multiple cancer cell lines like pancreatic,
ovarian etc. in vitro. We can develop our xenograft model either from patient derived
tumors cells and directly injecting them into nude mice near ovary region to induce tumor.
Follow the tumor growth, metastasis with and without administration of drug and record
the observations; based on our in vitro data we presume that there will be less tumor load
and metastasis with treatment of our drug. On the contrary we can develop a syngeneic
xenograft model with transformed ID8 epithelial cells in C57BL/6 mice model with intact
immune system.[140] This model will be more beneficial to understand the effect of our
drug on immune responses associated with tumor and tumor recognizing T cells. Studies
have shown that the cancer cells stay quiescent with unresolved ER stress, that prevent
these cells from proliferating and prevent T cell recognition of these cells and T cell
mediated killing.[141] As we know our dimer is a potent ER stress inducer, we can look at
the immune signaling and their effect on cancer cells with and without our dimer.
Successful completion of these studies in in vivo testing can take our studies further higher
level of therapeutic ladder i.e into clinical trials.
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